roche annual report finance report innovate healthcareinnovative solution span healthcare spectrum combine capability diagnostic pharmaceutical enable meet need entire healthcare spectrum identify disease suscep tibilitie screen disease atrisk population prevention diagnosis therapy treatment monitor innovative product advance fight disease wide range front make real difference patient health professional roche commitment innovate healthcare match commitment corporate social responsibility sustainability company guide value recognise economic social environmental concern inter twine progress sector require progress researchintensive company longterm strategic focus roche strive deliver sustainable value major stakeholderstable content finance report roche group finance brief finance brief financial review operating result nonoperate result cash flow net cash balance sheet roche security financial risk international financial reporting standard roche group consolidated financial statement income statement balance sheet cash flow statement statement recognise income expense statement change equity note roche group consolidated financial statement report group auditor multiyear overview supplementary net income ep information roche security roche holding ltd basel financial statement income statement balance sheet note financial statement appropriation available earning report statutory auditor finance report finance brief key result operate profit margin exceptional item local sale growth sale pharmaceutical diagnostic group change sales mchf mchf chf sales ebitda operating profit exceptional item profit exceptional item net income net cash equity equity ratio core eps dividend share continue business ebitda earning exceptional item financial income financing cost tax depreciation amortisation include impairment correspond operate profit exceptional item depreciation amorti sation include impairment definition core ep propose board director local currency finance executive team erich hunziker chief financial officer paul wouters management development peter eisenre taxis insurance marco frei pension asset management andreas knierzinger treasury steve krognes corporate development karl mahler investor relation erwin schneider accounting control finance report finance brief sale record sale pharmaceutical diagnostic increase local currency billion swiss franc oncology sale increase local currency billion swiss franc sale product mabtherarituxan billion swiss franc herceptin sale billion swiss franc avastin achieve sale billion swiss franc year market tamiflu sale reach billion swiss franc pandemic stockpile regular commercial sale operating result increase operating profit exceptional item local currency billion swiss franc improve profitability operate profit margin exceptional item percentage point investment manufacturing facility cash flow operating activity taxis increase billion swiss franc treasury operation positive net financial income million swiss franc compare net expense million swiss franc rating process finalise roche award rating moodys rating standardpoor reduction corporate debt billion swiss franc bond repay public debt offer genentech partly restructure exist finance lease financial condition increase net cash billion swiss franc billion swiss franc increase equity ratio decrease debtequity ratio net income decrease overall net income compare billion swiss franc result include billion swiss franc divest consumer health otc business increase profit continue business exceptional item billion swiss franc shareholder return increase share price swiss franc increase nonvoting equity security price swiss franc increase market capitalisation billion swiss franc increase ep core swiss franc increase propose dividend swiss francs finance report roche group financial review operating result group operating result sale continue business operate profit exceptional item billion chf growth billion chf sale annual result strong operating performance term topline growth profit margin mainly drive pharmaceutical division total sale grow local currency swiss franc dollar billion swiss franc pharmaceutical division contribute group sale diagnostic division represent incremental sale increase billion swiss franc achieve organic growth primarily drive strong demand group oncology drug avastin mabtherarituxan herceptin antiinfluenza drug tamiflu absolute term increase sale avastin compensate mark decline rocephin sale follow patent expiry united states july group operating profit exceptional item increase billion swiss franc correspond operate profit margin increase percentage point mainly result strong sale growth margin increase achieve time division continue increase investment launch prelaunch activity strong development pipeline addition gain product divestment million swiss franc low reporting cost group equity compensation plan employee operate expense significant overall impact increase cost compensate improve underlying result exclude equity compensation plan cost genentech far large plan group group operate profit margin exceptional item exchange rate impact sale operate profit growth minor average exchange rate dollar euro basically level japanese yen low average compare finance report roche group financial review group operating result pharmaceutical diagnostic corporate group mchf mchf mchf mchf sale operating profit exceptional item margin ebitda margin group operating result development result compare pharmaceutical diagnostic corporate group sale increase local currency operate profit exceptional item increase local currency margin percentage point increase ebitda increase local currency margin percentage point increase pharmaceutical operating result pharmaceutical division increase sale strongly local currency swiss franc dollar billion swiss franc outpace global market growth time operate profit exceptional item billion swiss franc represent growth consequently amargin increase percentage point marketing support significant important product mabtherarituxan herceptin avastin pegasyscopegus launch prelaunch activity notably tarceva boniva significant continued investment strong development pipeline pharmaceutical subdivision roche pharmaceutical genentech chugai contribute improved operating result exclude equity compensation plan cost genentech pharmaceutical operating profit margin exceptional item genentech operating profit margin exceptional item pharmaceutical division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item margin ebitda margin sale major growth driver key product oncology transplantation virology franchise include tamiflu franchise significantly outpace respective market renal anemia franchise grow modestly slight decline finance report roche group financial review pharmaceutical division sale franchise sale change franchise mchf sale local currency oncology transplantation virology renal anemia total exclude tamiflu product line show sale growth especially notable pharmaceutical product strong growth product grow product rocephin dilatrend decline patent expiry respectively growth profitability pharmaceutical division primarily product tamiflu avastin mabtherarituxan herceptin tarceva cellcept xeloda pegasyscopegus xolair neorecormonepogin represent portfolio generate billion swiss franc additional sale pharmaceutical division sale product change sale local mchf sale currency franchise mabtherarituxan oncology neorecormonepogin anemia oncology herceptin oncology cellcept transplantation avastin oncology tamiflu virology pegasys virology rocephin infectious disease xeloda oncology xenical metabolic disorder kytril oncology nutropinprotropin metabolic disorder xolair respiratory disease copegus virology cymevenevalcyte transplantation pulmozyme respiratory disease tarceva oncology neutrogin oncology dilatrend cardiovascular disease activasetnkase cardiovascular disease total product product total mabtherarituxan increase primarily drive high mabthera sale volume market europe rest world increase market penetration indolent aggressive non hodgkin lymphoma application expand product indication include maintenance treatment indolent nonhodgkin lymphoma file december plan finance report roche group financial review neorecormonepogin sale growth europe mainly drive increase use oncology setting weekly prefille syringe compensate continued price erosion renal anemia indication neorecormon sale oncology increase compare market growth japan epogin grow line market herceptin growth strong europe drive extension treatment duration increase firstline penetration addition clinical datum show significant efficacy adjuvant breast cancer lead grow adoption unapproved area group plan file indication quarter cellcept growth support region cellcept continue clear market leader mycophenolic acid mpa market market share avastin sale growth drive strong increase uptake treatment colorectal cancer firstline relapsedrefractory setting follow approval january avastin launch key country germany major sale contributor group plan filing extend label match label filing metastatic nonsmall cell lung cancer nsclc metastatic breast cancer base excellent clinical datum receive early year tamiflu sale drive pandemic stockpiling government sale commercial seasonal sale sale end country place order pandemic supply delivery spread revenue tamiflu pandemic contract recognise risk reward ownership product transfer customer delivery customer case billandhold arrangement prior final delivery customer inventory specifically identify ready delivery delivery customer pegasyscopegus pegasys share global pegylate interferon market sale increase drivenby high pegasys sale volume european market market share increase market expansion base new indication hepatitis virus normal alt coinfection hiv sale increase modestly include singledigit price increase marketing application combine pegasys andcopegus hepatitis designate priority review japanese regulatory agency mhlw xeloda continue growth achieve region primarily drive obtain approval new indication adjuvant monotherapy treatment colon cancer receive april june xolair sale growth drive increase patient prescriber base extent price increase effective july xolair humanize antiige antibody approve treatment moderatetosevere persistent allergic asthma adult adolescent tarceva major contributor sale tarceva approve november treatment patient locally advanced metastatic nonsmall cell lung cancer nsclc failure atleast prior chemotherapy regimen swiss canadian approval receive march july respectively european approval receive september tarceva launch ingermany france tarceva launch country reimbursement approval food drug administration fda approve tarceva treatment inoperable metastatic pancreatic cancer november roche file application indication regulators october rocephin expect sale decline markedly follow expiry product patent july information product pipeline find appropriate section business report finance report roche group financial review sale region sale continue grow major region north america sale grow time fast market drive product market genentech avastin mabtherarituxan herceptin tarceva xolair tamiflu cellcept xeloda compensate million swiss franc decline sale rocephin follow patent expiry july europe group continue gain market share drive continue strong sale growth tamiflu mabtherarituxan herceptin avastin pegasys neorecormon xeloda cellcept sale growth japan primarily drive tamiflu late severe influenza season early influenza season neutrogin epogin herceptin pegasy overall sale japan grow close time fast japanese market pharmaceutical division sale region sale change region mchf sale local currency north america europe japan region total royalty operate incomethe decrease low gain product divestment million swiss franc compare million swiss franc include disposal soriatane partly offset high royalty income notably genentech new licence arrangement imclone sale erbitux include onetime payment relate royalty erbitux sale launch product signing agreement january royalty income genentech increase high sale licensee product high outlicense income roche pharmaceutical particular milestone income follow fda approval boniva united states cost sale increase local currency line increase sale economy scale production include benefit focusse small number production site continue productivity improvement product mix effect factor compensate increase royalty expense product sale million swiss franc million swiss franc drive success product mabtherarituxan tarceva xolair particular tamiflu marketing distributionthese cost increase local currency low growth sale take account ongoing strong support establish product global launch activity newly launch product avastin tarceva boniva prelaunch cost product mabtherarituxan rheumatoid arthritis lucentis marketing distribution percentage sale decline percentage point compare research developmentthe increase million swiss franc local currency billion swiss franc reflect ongoing clinical development product pipeline high expense earlystage project research development cost percentage sale percentage point ratio comparative period include substantial inlicense latestage development commercialisation jtt japan tobaccos innovative cholesteryl ester transfer protein cetp inhibitor treatment dyslipidemia finance report roche group financial review general administrationthe overall increase million swiss franc local currency item gilead retrospective adjustment relate high sap implementation cost genentech charitable contribution genentech low gain disposal property plant equipment transition impact expense equity compensation plan genentech high restructuring cost roche pharmaceutical chugai contribute percentage point growth exclude item general administration cost grow growth sale increase drive creation new business eastern europe roche pharmaceuticals alignment infrastructure genentech arise continue strong growth business amortisation impairment intangible asset decline solely genentech firstly intangible asset fully amortise mid mid secondly genentech decide stop commercialisation nutropin depot result impairment nutropin depot intangible asset million swiss franc thirdly genentech impair inlicense compound million swiss franc pharmaceutical subdivisional result operate operate profit profit exceptional exceptional sale ebitda ebitda item item mchf mchf sale mchf sale roche pharmaceutical genentech chugai pharmaceutical division roche pharmaceutical genentech chugai pharmaceutical division overall pharmaceutical division show strong sale increase subdivision result improve operating margin margin genentech adversely impact expense employee stock option exclude margin increase percentage point chugai improve sale performance particularly tamiflu beneficial impact overall cost structure follow chugais early retirement plan implement second half main driver margin improvement additional information pharmaceutical division subdivisional result give note consolidated financial statement information genentech chugai give note diagnostic operating result diagnostic division increase sale billion swiss franc grow local currency swiss franc dollar maintain lead market position operating profit exceptional item decrease local currency billion swiss franc margin industry average margin decline percentage point primarily dueto heavy price pressure market additionally high relative cost sale growth drive startup cost new manufacturing facility new product high depreciation increase volume instrument placement finance report roche group financial review diagnostic division result change change mchf mchf chf local currency sale royalty operate income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item margin ebitda margin sale major driver sale growth centralize diagnostic immunochemistry molecular diagnostic number key diagnostic product launch help contribute slightly increase growth second half include launch complete new product portfolio diabetes care innovative product offering new market segment dna sequence diagnostic division sale business area sale change business area mchf sale local currency diabetes care centralize diagnostic immunochemistry molecular diagnostic near patient testing apply science total diabetes care diabete care maintain number position sale blood glucose monitoring meter strip lancet increase local currency billion swiss franc insulin delivery sale grow million swiss franc exception growth strong second half launch new product completely rejuvenate accuchek portfolio new accuchek aviva meter complete global launching october track reverse market share decline maturation accuchek advantage line accuchek compact plus remain meter market integrating measure test strip lancet device rapidly grow new segment rollout nearly complete launch plan quarter global launch accuchek multiclix incorporate lancet complete strengthen group range area insulin delivery group increase market share germany follow successful launch accuchek spirit pump accuchek flexlink infusion set business area ready launch new insulin pump customer soon food drug administration fda provide goahead centralize diagnostic sale increase local currency billion swiss franc despite ongoing price pressure laboratory segment immunochemistry sale increase billion swiss franc placements elecsys platform increase aggressive placement strategy increase demand cardiac test elecsy probnp clinical chemistry affect pricing pressure business area assume market leadership clinical laboratory segment quarter finance report roche group financial review molecular diagnostic blood screen continue provide majority growth increase local currency million swiss franc decrease pool size japan combine german red cross centre korea come online additionally fda clearance cobas ampliscreen hbv test screen blood plasma ampliscreen hiv hbv hcv test expand use screen live cadaveric organ tissue donation sale virology grow local currency million swiss franc support introduction new fully automate platform help maintain market share overcome pricing pressure near patient testing coagulation sale increase local currency million swiss franc increase adoption test doctor office grow trend patient self monitor blood gaselectrolyte sale rise local currency million swiss franc strong placement blood gaselectrolyte instrument particularly japan latin america sales cardiac reader grow local currency million swiss franc launch cardiac ntprobnp test second half start impact introduction new selfcoagulation monitor device coaguchek commence pilot country quarter apply science life science market grow strong competitive environment business area sale experience slightly low growth year see number major product launch particularly launch new highthroughput lightcycler system entrance time profitable dna sequence market launch genome sequencer system exclusive distribution agreement life science sale region sale continue grow ahead local market region exception north america sale decline slightly sale region primarily affect decline sale diabetes care roche lead diagnostic supplier japan diagnostic division sale region sale change region mchf sale local currency north america emea japan region total europe middle east africa excl iberia royalty operate income million swiss franc royalty operating income remain basically level royalty income decline million swiss francsdue expiry foundational pcr patent substantial oneoff royalty income bioveris million swiss franc comparative period outlicense income million swiss franc mainly contract company applera abbott genprobe molecular diagnostic compensate decline royalty income cost sale overall increase local currency sale growth cost good sell increase rate twice high sale addition heavy selling price pressure production startup cost new product new molecular diagnostic manufacturing facility branchburg furthermore production cost high product enhance customer feature high depreciation high volume instrument placement regulatory compliance cost increase royalty expense million swiss franc low million swiss franc compare absence royalty pay igen igen acquire group finance report roche group financial review marketing distribution increase local currency slightly increase sale dueto launch number new diabetes care product accuchek aviva blood glucose meter europe marketing distribution percentage sale remain stable research development cost grow local currency sale major project coaguchek accuchek aviva research development cost peak percentage sale research development cost decline slightly percentage point general administration cost decrease local currency strict cost control low sap implementation cost amortisation impairment intangible asset increase partially amortisation intangible asset acquire igen acquisition result include charge million swiss franc compare million swiss franc represent month acquisition march amortisation expense recently acquire licence distribution right account rest increase corporate operating cost general administration cost decline million swiss franc million swiss franc include result gain million swiss franc return chugais welfare pension fund japanese government november result include million swiss franc administration cost previously allocate consumer health otc business item transfer sale business reclassify business segment corporate cost restructure away absorb business segment roche pharmaceutical chugai exceptional operating item exceptional operating item pharmaceutical diagnostic corporate group mchf mchf mchf mchf mchf mchf mchf mchf operating profit exceptional item amortisation goodwill major legal case change group organisation operate profit amortisation goodwill follow change international financial reporting standard amortisation goodwill cease effective january impairment goodwill record major legal case provision certain litigation arbitration matter pharmaceutical division increase million swiss franc diagnostic division million swiss franc provision record base current litigation settlement negotiation recent settlement agreement additional information give note consolidated financial statement change group organisation significant development additional income expense record operating profit increase million swiss franc local currency reflect continue improvement group operate performance low exceptional item drive amortisation goodwill finance report roche group financial review nonoperate result nonoperate result change mchf mchf chf operating profit associate company financial income financing cost exceptional income bond conversion redemption profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest group treasury operation deliver positive net financial income net income financial asset foreign exchange management exceeding financing cost million swiss franc group effective tax rate reduce percentage point mainly discontinuation amortisation goodwill january profit continue business increase combination positive development operate financial tax line compensate exceptional financial income result exclude aftertax income million swiss franc exceptional operating item profit continue business increase billion swiss franc net income low million swiss franc billion swiss franc duetothe inclusion billion swiss franc divest consumer health otc business associate company result associate significant net financial income continue business million chf financing cost financial income net financial income financial income financial income show improvement compare net income equity security million swiss franc compare million swiss franc drive strongly perform equity market disposal equity investment low impairment investment interest income income debt security double million swiss franc high holding increase interest rate net foreign exchange loss million swiss franc compare gain million swiss franc analysis financial income give note consolidated financial statement financing cost finance cost million swiss franc reduction mainly retirement debt instrument bank debt low average level debt offset increase interest rate float rate debt analysis financing cost give note consolidated financial statement finance report roche group financial review exceptional income bond conversion redemption continue refinance restructure group debt lyon lyon iii note call redemption group redeem chameleon bond public tender additionally group reassess likely future cash outflow lyon note conclude appropriate consider date july probable date cash flow net pretax gain million swiss franc arise transaction primarily group partial disposal interest genentech conversion lyon note income taxis group effective tax rate compare rate main influence discontinuation goodwill amortisation result reduce rate percentage point underlie tax rate broadly unchanged increase relative contribution genentech chugai group overall result largely offset use research development tax credit areconciliation effective tax rate give note consolidated financial statement profit continue business billion chf net income billion chf profit continue business increase compare positive development operate financial tax line offset exceptional financial income million swiss franc aftertax result exclude exceptional item profit continue business increase billion swiss franc discontinue business result include operate result remain otc consumer health business transfer bayer comparative result include billion swiss franc divestment gain sale initial business bayer billion swiss franc operating result otc consumer health business fully own roche group end information discontinue business give note consolidated financial statement net income group net income decrease billion swiss franc return sale margin net income attributable roche shareholder lower comparative period include billion swiss franc divest consumer health otc business exceptional financial income billion swiss franc aftertax share net income attributable minority increase million swiss franc continually improve profit contribution genentech chugai million swiss franc attributable genentech minority interest million swiss franc chugai minority interest dilute eps chf chf change group continue business continue business exceptional item core decrease dilute eps increase higher underlying net income offset exceptional item include result core ep exclude exceptional item amortisation intangible asset increase chf chf show underlying improvement group operate financial tax result supplementary net income ep information give include calculation profit continue business exceptional item core ep reconcile group publish ifrs result finance report roche group financial review cash flow net cash cash flow operating activity net cash income taxis billion chf billion chf condense cash flow statement mchf mchf cash generate operation increase decrease work capital cost major legal case pay operating cash flow operating activity income taxis income taxis pay activity operating activity invest activity financing activity net effect currency translation cash increase decrease cash consolidated cash flow statement give consolidated financial statement operate cash flow group business operation continue strong cash generation billion swiss franc drive continued growth ebitda tax payment considerably higher mainly payment tax gain disposal consumer health otc business increase payment genentech chugai overall operating cash flow increase billion swiss franc invest cash flow large invest cash flow receipt bayer billion swiss franc proceed divestment consumer health otc business receive january invest cash flow include expenditure property plant equipment billion swiss franc particular billion swiss franc genentech purchase oceanside biologics manufacturing facility increase net investment marketable security billion swiss franc mainly result strong cash generation operate business large net cash inflow sale group portfolio marketable security order fund repayment debt instrument finance cash flow significant financing cash flow relate dividend payment redemption debt instrument dividend pay billion swiss franc billion swiss franc cash redemption debt instrument billion swiss franc sumo bond compare billion swiss franc lyon iii note chameleon bond redemption conversion lyon note cash impact million swiss franc debt obligation entirely settle delivery genentech share genentech issue billion dollar senior note result cash inflow equivalent billion swiss franc genentech billion swiss franc repay finance lease obligation genentech receive billion swiss franc stock option exercise period genentech repurchase share billion swiss franc finance report roche group financial review net cash december december mchf mchf change cash cash equivalent marketable security longterm debt shortterm debt net cash net cash increase significantly main driver strong cash inflow operating activity billion swiss franc receipt billion swiss franc bayer payment property plant equipment stock option exercise repurchase genentech reduce net cash total billion swiss franc payment dividend reduce net cash billion swiss franc sumo redemption issue genentech senior note repayment finance lease genentech reduce debt cash overall effect net cash shortterm debt reduce billion swiss franc balance sheet balance sheet billion chf liability asset net asset equity condense balance sheet december december mchf mchf change property plant equipment goodwill intangible asset noncurrent asset cash marketable security current asset total asset debt current noncurrent noncurrent liability current liability total liability total net asset capital reserve attributable roche shareholder equity attributable minority interest total equity consolidated balance sheet give consolidated financial statement finance report roche group financial review noncurrent asset increase dollar swiss franc december december increase longterm asset swiss franc term group production facility intangible asset denominate dollar purchase oceanside biologic manufacturing facility genentech increase property plant equipment billion swiss franc acquisition glycart increase goodwill intangible asset billion swiss franc follow decision california supreme court february review litigation genentech city hope surety bond billion swiss franc post genentech reclassify current asset longterm asset current asset overall current asset increase increase liquid fund group strong operating performance matter describe section cash flow net cash receipt billion swiss franc bayer consumer health otc business increase cash decrease current asset debt net effect issue genentech senior note repayment finance lease genentech increase debt billion swiss franc redemption sumo bond reduce debt billion swiss franc additionally movement dollar exchange rate increase swiss franc carry value group dollardenominate debt instrument noncurrent current liability provision billion swiss franc genentech city hope litigation reclassify current liability noncurrent liability total net assetsequity significant movement net income billion swiss franc dividend payment billion swiss franc currency translation gain billion swiss franc currency translation gain mainly arise increase dollar relative swiss franc particularly affect balance sheet value asset liability particular concentration inthe property plant equipment goodwill intangible asset debt strong financial condition group remain solidly finance equity include minority interest represent total asset total asset finance longterm roche security price development roche security perform significantly well swiss market peer group healthcare company roche share price close year swiss franc compare price swiss franc end roche nonvoting equity security genussschein close year swiss franc compare price swiss franc end previous year comparison smi gain market capitalisation roche billion swiss franc end compare billion swiss franc end roche leader peer group term total shareholder return tsr share price growth plus dividend yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group peer group abbott laboratories altana amgen astrazeneca bayer becton dickinson biogen idec bristolmyers squibb elililly glaxosmithkline johnson johnson merck novartis pfizer serono sanofiaventis schering scheringplough takeda wyeth finance report roche group financial review total shareholder return development price tsr roche roche share peer group actual exchange rate roche roche share peer group dividend board director propose increase dividend swiss franc share nonvoting equity security swiss franc approval annual general meeting consecutive increase dividend dividend proposal approve shareholder dividend payment share nonvoting equity security issue billion swiss franc billion swiss franc result payout ratio base price yearend dividend yield roche share yield nonvoting equity security information roche security give finance report information share nonvoting equity security information share nonvoting equity security chf chf change basic eps diluted eps group continue business continue business exceptional item core equity attributable roche shareholder share dividend share detail refer note consolidated financial statement finance report financial risk valueatrisk earningsatrisk analysis tool valueatrisk var calculation indicate range value respective asset liability fluctuate certain probability certain time period hold period var measure statistical measure implicitly assume value change recent past indicative value change future market shock include calculation recently observe group conduct additional stress testing possibility consideration group use statistically relevant observation period apply hold period reflect time period require change respective risk exposure deem appropriate long hold period probability high value change increase var measure finance report roche group financial review earningsatrisk ear equivalent var methodology potential value change indicate potential change profit loss certain probability certain time period constraint limitation apply methodology var ear methodology refine hold period set trading day enhance calculation model introduce var ear figure interest rate risk measure historical simulation approach deltanormal approach historical scenario represent price rate change individual instrument specific day period past year financial instrument fully revalue valuation model total change value earning determine var ear calculation base confidence level hold period trading day comparative information restate group predict future market movement var ear figure give represent actual loss expect incur financial asset liability possible bad loss period state consider effect favourable change market rate foreign exchange risk group exposure movement foreign currency affect net income financial position asexpresse swiss franc summarise follow key figure comment growth continue business local local currency currency chf chf sale operating profit exceptional item exchange rate swiss franc december average december average usd eur gbp jpy average major currency remain stable swiss franc consequently difference sale growth continue business operate profit growth express swiss franc local currency absolute term sensitivity group sale continue business change dollar swiss franc swiss franc approximately million swiss franc correspond sensitivity euro yen approximately million swiss franc million swiss franc respectively group pursue strategy continuously lockin favourable development foreign exchange rate enter derivative contract reduce exposure potential future movement foreign exchange rate foreign exchange transaction var remain low level foreign exchange risk december december mchf mchf change var monetary position finance report roche group financial review interest rate risk interest rate risk arise movement interest rate adverse effect group netincome financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument appropriate group use financial derivative swap manage interest rate risk genentech issue new bond billion dollar despite group debt increase bybillion chf redemption outstanding debt bank debt capitalise lease sumo bond order achieve well match term structure asset liability group swap sizeable remain debt float interest rate consequence exposure potential change interest rate decrease interest rate var measure potential change net market value interest rate sensitive asset liability decline interest rate var consider roche interest rate sensitive position comparatively small risk repricing refinancing contain reasonable level earningsatrisk ear increase mainly result liquid fund hold short interest rate commitment generally high interest rate level allow room downward change interest rate interest rate risk december december mchf mchf change var instrument sensitive interest rate ear instrument sensitive interest rate market risk financial asset liability change market value financial asset liability affect net income financial position group market risk arise movement stock price interest rate foreign exchange rate group financial asset hold highly liquid fix income money market instrument currency allocation maturity profile financial asset financial liability align equity allocation group portfolio cash marketable security reduce billion swiss franc total cash marketable security billion swiss franc december total cash marketable security international financial reporting standard roche group international financial reporting standard ifrs report consolidated result late international accounting standard board iasb publish number new revise standard effective group implement january fully discuss note consolidated financial statement goodwill amortisation effective january amortisation goodwill cease goodwill continue test impairment change require prospective application standard apply goodwill amortisation expense million swiss franc continue business record operating result net income attributable roche shareholder million swiss franc higher sharebased payment fair value equity compensation plan award employee estimate grant date record expense vest period change require retrospective application certain transitional requirement apply transitional requirement impact previously report operating income net income attributable roche shareholder million swiss franc million swiss franc respectively transitional requirement indicative future impact finance report roche group financial review recognition intangible asset revise standard intangible asset business combination typically result intangible asset recognise acquisition inlicense collaboration alliance previously approximately million swiss franc previously expense research development expense capitalise intangible asset standard require prospective application financial instrument group fully apply previous ias financial instrument additional change implement standard financial instrument require retrospective application significant effect equity minority interest minority interest include group equity separate category balance sheet increase group equity million swiss franc apply retrospectively january presentation income statement follow change group revise presentation income statement include divisional split group operating result change accordance requirement new revise standard order improve comparability result healthcare company allow reader accurate assessment sustainable earning capacity group comparative result consolidate financial statement restate new format detail change give note consolidated financial statement supplementary presentation material investor update hold march available investor relation section group website wwwrochecom finance report roche group consolidated financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item amortisation goodwill major legal case change group organisation operating profit associate company financial income financing cost profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest continue earning share nonvoting equity security business group basic chf diluted chf finance report roche group roche group consolidate financial statement consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income cost sale marketing distribution research development general administration amortisation impairment intangible asset operate profit exceptional item amortisation goodwill major legal case change group organisation operating profit associate company financial income financing cost exceptional income bond conversion redemption profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest continue earning share nonvoting equity security business group basic chf diluted chf disclose note income statement restate follow change ifrs adopt effective january reconciliation previously publish income statement provide note finance report roche group roche group consolidate financial statement consolidate balance sheet million chf december december noncurrent asset property plant equipment goodwill intangible asset investment associate company financial longterm asset longterm asset defer income tax asset postemployment benefit asset total noncurrent asset current asset inventory account receivable current income tax asset current asset receivable bayer group collect january marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer income tax liability postemployment benefit liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable minority interest total equity disclose note balance sheet restate follow change ifrs adopt effective january reconciliation previously publish balance sheet provide note finance report roche group roche group consolidate financial statement consolidated cash flow statement million chf year end december cash flow operating activity cash generate operation increase decrease work capital vitamin case payment major legal case payment define benefit postemployment plan utilisation restructure provision utilisation provision operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset disposal product acquisition subsidiary associate company divestment discontinue business subsidiary associate company interest dividend receive sale marketable security purchase marketable security invest cash flow total cash flow invest activity cash flow financing activity proceed issue longterm debt instrument repayment longterm debt instrument increase decrease longterm debt transaction equity instrument increase decrease shortterm borrowing interest dividend pay exercise equitysettle equity compensation plan genentech chugai share repurchase finance cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december finance report roche group roche group consolidate financial statement consolidate statement recognise income expense million chf year end december availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation income taxis item take directly transfer equity net income recognise directly equity net income recognise income statement total recognise income expense attributable roche shareholder minority interest total effect change accounting policy attributable roche shareholder minority interest total finance report roche group roche group consolidate financial statement consolidate statement change equity millions chf roche minority shareholder interest total year end december january previously report change accounting policy january restate net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase convertible debt instrument change minority interest december year end december january net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase convertible debt instrument change minority interest december finance report note roche group consolidate financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard ifrs interpretation adopt international accounting standard board iasb comply swiss law prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve issue board director january subject approval annual general meeting shareholder february preparation consolidated financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure ofcontingent liability date financial statement future estimate assumption base management good judgement date financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change change accounting policy arise application new revise standard interpretation apply retrospectively specify transitional requirement particular standard interpretation retrospective application require result comparative period opening balance period restate new accounting policy apply addition comparative reclassify extend previously report result account presentational change consolidation policy financial statement consolidate financial statement roche holding ltd company register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enterprise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right potential voting right company share capital special purpose entity consolidate substance relationship special purpose entity control group company acquire year consolidated date control transfer group subsidiary divest include date control pass group inter company balance transaction result unrealised income eliminate investment associate company account equity method company group exercise power exercise significant influence control normally evidence group own voting right potential voting right company balance transaction associate company result unrealised income eliminate extent group interest associate company interest joint venture report linebyline proportionate consolidation method segment report group primary format segment report business segment secondary format geographical segment risk return group operation primarily determine different product group produce geographical location group operation reflect group management organisational structure internal financial reporting system finance report roche group note roche group consolidate financial statement determination group business geographic segment base organisation unit information report group management group division pharmaceutical diagnostic pharmaceutical division subdivision roche pharmaceutical genentech chugai subdivision separate management reporting structure pharmaceutical division consider separately reportable business segment vitamin fine chemical business consumer health otc business previously separately reportable business segment divest present discontinued business certain headquarter activity report corporate consist corporate headquarters include corporate executive committee corporate communication corporate human resource corporate finance include treasury taxis pension fund management corporate legal safety environmental service group geographical segment determine geographical location similarity economic environment transfer price business segment set arm length basis divisional asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory segment asset liability consist asset liability reasonably attribute report business segment include pension assetsliabilitie provision non segment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment debt capital expenditure comprise addition goodwill intangible asset property plant equipment include arise acquisition foreign currency translation group company use local currency functional currency certain group company use currency dollar swiss franc euros functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity defer equity consolidation asset liability group company functional currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity disposal foreign entity identify cumulative currency translation difference equity relate foreign entity recognise income gain loss divestment revenue cost sale sale represent amount receive receivable good supply customer deduct trade discount cash discount volume rebate exclude sale value add taxis revenue sale product recognise transfer customer significant risk reward usually shipment trade discount cash discount volume rebate record accrual basis consistent recognition related sale estimate expect sale return chargeback rebate include medicaid united states similar rebate country deduct sale record accrue liability provision estimate base analyse exist contractual legislativelymandate obligation historical trend group experience revenue record earn service perform necessary single transaction split separately identifiable component reflect substance transaction conversely transaction consider revenue recognition purpose commercial effect understand reference series transaction cost sale include correspond direct production cost relate production overhead good sell service render startup cost validation achievement normal production capacity expense incurred finance report roche group note roche group consolidate financial statement royalty income expense royalty income expense recognise accrual basis royalty expense directly link good sell include cost sale royalty expense include general administration research development addition internal research development activity group party inlicense similar arrangement alliance partner furthermore group acquire inprocess research development asset business combination purchase specific asset internal research cost charge income incur internal development cost capitalise intangible asset identifiable asset generate expect future economic benefit cost asset measure reliably group currently internal development cost qualify capitalisation intangible asset internal development cost charge income incur criterion recognition asset meet inprocess research development asset acquire inlicense arrangement business combination separate purchase capitalise intangible asset describe available use intangible asset amortise straightline basis period expect benefit review impairment balance sheet date license milestone upfront receipt payment certain group company receive party upfront milestone similar nonrefundable payment relate sale licensing product technology revenue associate performance milestone recognise base achievement deliverable define respective agreement non refundable upfront payment licence fee initially report deferred income recognise revenue income earn period development collaboration manufacturing obligation payment group company party associate company item capitalise intangible asset receipt payment consolidate subsidiary genentech chugai roche group subsidiary eliminate consolidation taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable intention remit earning defer income tax asset liability recognise temporary difference tax basis asset liability carry amount financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis levy taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate discontinue business noncurrent asset hold sale discontinue business component group business represent separate major line business geographical area operation subsidiary acquire exclusively view resale reclassification discontinue business occur disposal operation meet criterion classify hold sale early finance report roche group note roche group consolidated financial statement disposal group group assets dispose group single transaction liability directly associate asset transfer transaction asset liability disposal group reclassify heldforsale value recover principally sale continue use disposal group available sale current condition sale highly probable immediately classification heldforsale measurement asset liability disposal groupis bring uptodate accordance applicable accounting policy initial reclassification heldforsale disposal group recognise low carrying fair value cost sell impairment loss initial classification heldforsale include income statement employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned liability longterm employee benefit discount account time value money material pension postemployment benefit employee cover define benefit define contribution postemployment plan sponsor group company accounting report define benefit plan base recent actuarial valuation define benefit obligation service cost calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return plan asset discount rate base market yield highquality corporate bond country concern difference assumption actual experience effect change actuarial assumption allocate estimate average remain work live employee difference exceed define corridor past service cost allocate average period benefit vested expense define benefit plan charge theappropriate income statement head operating result pension plan administration funding oversee corporate level settlement gain loss result change funding arrangement report general administration expense corporate business segment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan recognition pension asset limit net total unrecognised actuarial loss past service cost present value future refund plan reduction future contribution plan group contribution define contribution plan charge income statement year relate equity compensation plan certain employee group participate equity compensation plan include separate plan genentech chugai fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record subsequent cash flow exercise vested award record increase equity cashsettle plan liability record measure fair value balance sheet date movement fair value record appropriate income statement head operating result subsequent cash flow exercise vested award record reduction liability finance report roche group note roche group consolidate financial statement property plant equipment property plant equipment initially record cost purchase construction depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate item estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incurred borrowing cost capitalise lease lease property plant equipment group substantially risk reward ownership classified finance lease finance lease capitalise start lease fair value present value minimum lease payment low rental obligation net finance charge report debt asset acquire finance lease depreciate accordance group policy property plant equipment interest element lease payment charge income lease term base effective interest rate method lease substantially risk reward ownership transfer group classify operating lease payment operating lease charge income straightline basis period lease group lessor assets subject finance lease report receivables equal net investment lease asset subject operating lease report property plant equipment lease income finance lease recognise term lease base effective interest rate method lease income operating lease recognise lease term straightline basis business combination goodwill business combination account purchase method accounting cost acquisition consideration give exchange control identifiable asset liability contingent liability ofthe acquire company consideration include cash pay plus fair value date exchange asset give liability incur assume equity instrument issue group cost acquisition include directly attributable cost acquire net asset identifiable asset liability contingent liability initially recognise fair value group acquire ownership acquire company minority interest record minoritys proportion fair value acquire net asset goodwill record surplus cost acquisition group interest fair value acquire net asset goodwill fair value adjustment record asset liability acquire company record local currency company goodwill amortise assess possible impairment balance sheet date additionally test annually impairment goodwill arise investment associate company surplus cost investment group share fair value net identifiable asset goodwill record investment associate company finance report roche group note roche group consolidate financial statement intangible asset patent licence trademark intangible asset initially record cost asset acquire business combination fair value allocate acquisition accounting acquire business combination initial fair value cost intangible asset amortise useful life straightline basis beginning point available use estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review amortisation impairment intangible asset present separately income statement materiality amount order fairly present group result impairment property plant equipment intangible asset evidence asset impair recoverable asset calculate animpairment assessment carry recoverable asset high fair value cost sell value use carrying carry reduce recoverable value reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment loss arise useful life asset question review necessary future depreciationamortisation charge accelerate impairment financial asset discuss financial asset policy impairment goodwill impairment assessment goodwill carry annually goodwill allocate cashgenerating unit group business segment recoverable cashgenerate unit high fair value cost sell value use carrying impairment carrying record methodology impairment testing cashgenerating unit describe note inventory inventory state low cost net realisable value cost finish good work process include raw material direct labour directly attributable cost overhead base normal capacity production facility borrowing cost include cost determine weighted average method net realisable value estimate selling price cost completion selling expense account receivable account receivable carry original invoice allowance doubtful account allowance record difference carry recoverable objective evidence group able collect amount longterm account receivable discount account time value money material provision sale return sale chargeback report provision accrue liability respectively cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash readily convertible know amount cash subject insignificant risk change value maturity month date acquisition definition cash flow statement provision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise take account foreign currency effect arise translation functional currency swiss franc time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable finance report roche group note roche group consolidate financial statement fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price use establish estimation technique option pricing model estimate discount value cash flow fair value financial asset liability balance sheet date approximately line report carry value specifically mention note consolidated financial statement financial asset financial asset principally investment include marketable security classify fairvalue throughprofitorloss availableforsale heldtomaturity loan receivables fairvaluethrough profitorloss financial asset classify heldfortrade designate initial recognition heldfortrade financial asset acquire principally generate profit shortterm fluctuation price financial asset designate fairvaluethroughprofitorloss result relevant information eliminate measurement recognition inconsistency heldtomaturity financial asset security fix maturity group intent ability hold maturity loan receivables loan longterm financial asset create group acquire issuer primary market nonderivative financial asset fix determinable payment financial asset consider availableforsale financial asset initially record fair value include transaction cost asset designate fairvaluethroughprofitorloss exclude transaction cost purchase sale recognise settlement date fairvaluethroughprofitorloss financial asset subsequently carry fair value change fair value record financial income period arise heldtomaturity financial asset subsequently carry amortise cost effective interest rate method availableforsale financial asset subsequently carry fair value unrealise change fair value record equity availableforsale financial asset sell impair dispose cumulative gain loss previously recognise equity include financial income current period loan receivables subsequently carry amortise cost financial asset assess possible impairment balance sheet date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale financial asset market value original cost net previous impairment consider impaired availablefor sale financial asset market value original cost net previous impairment sustain sixmonth period consider impaired decrease market price original cost net previous impairment sustained sixmonth period consider objective evidence impairment movement fair value record equity objective evidence impairment asset sell dispose financial asset carry amortise cost impairment charge difference carry value recoverable calculate estimate future cash flow discount original effective interest rate availableforsale financial asset impairment charge currently carry equity difference original cost net previous impairment fair value financial asset derecognise contractual right cash flow asset expire group sell dispose contractual right cash flow include situation group retain contractual right assume contractual obligation pay cash flow party derivative derivative financial instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income period arise embed derivative recognise separately closely related host contract host contract carry amortise cost finance report roche group note roche group consolidate financial statement hedge purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time future cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income qualify cash flow hedge hedge instrument record fair value portion change infairvalue effective hedge include equity remain ineffective portion report financial income hedge relationship hedge firm commitment highly probable forecast transaction result recognition nonfinancial asset liability cumulative change fair value hedge instrument record equity include initial carrying value asset liability date recognition qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income hedge instrument derivative equity case entity dispose cumulative change fair value hedge instrument record equity reclassify income debt instrument debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost effective interest method discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method certain debt instrument designate fairvaluethroughprofitorloss result relevant information eliminate significantly reduce measurement recognition inconsistency previously occur instrument subject qualify fair value hedge debt instrument report fair value base quote price active market movement fair value report financial income debt instrument designate fairvaluethroughprofitorloss disclose note bifurcation carry issue convertible debt instrument initial carry value liability element calculate market interest rate equivalent nonconvertible instrument remainder net proceed allocate equity conversion option report equity defer income tax liability liability element subsequently report amortise cost fairvaluethrough profitandloss designate finance report roche group note roche group consolidate financial statement equity instrument group holding equity instrument record deduction equity original cost acquisition consideration receive subsequent resale equity instrument movement report change equity instrument acquire primarily meet obligation arise respect certain group debt instrument management judgement apply accounting policy application group accounting policy require management judgement apart involve estimate significant effect amount recognise consolidated financial statement management judgement particularly require assess substance transaction complicate structure legal form include limited follow area revenue recognition nature group business sale transaction simple structure sale agreement consist multiple component occur different time group party outlicensing agreement involve upfront milestone payment occur year agreement involve certain future obligation revenue recognise management judgement significant risk reward ownership transfer group retain continue managerial involvement effective control good sell obligation fulfil transaction result cash receipt initially recognise deferred income release income subsequent period basis performance condition specify agreement lease group party leasing arrangement lessor lessee treatment leasing transaction financial statement mainly determine lease consider operate lease finance lease make assessment management look substance lease legal form make judgement substantially risk reward ownership transfer key assumption source estimation uncertainty preparation consolidate financial statement conformity ifrs require management estimate assumption affect application policy report amount asset liability income expense relate disclosure estimate underlying assumption base historical experience factor believe reasonable circumstance result form basis make judgement carry value asset liability readily apparent source actual result differ estimate estimate underlying assumption review ongoing basis change accounting estimate necessary change circumstance estimate base result new information experience change recognise period estimate revise key assumption future key source estimation uncertainty significant risk cause material adjustment carry value asset liability month describe finance report roche group note roche group consolidate financial statement revenue recognition group accrual provision expect sale return chargeback rebate include medicaid united states similar rebate country december total million swiss franc estimate base analyse exist contractual legislativelymandate obligation historical trend group experience management believe total accrual provision item adequate base currently available information deduction base management estimate subject change well information available change arise impact accrual provision recognise balance sheet future period consequently level sale recognise income statement future period property plant equipment intangible asset include goodwill group property plant equipment carry value million swiss franc disclose note goodwill carry value million swiss franc note intangible asset carry value million swiss franc note asset review annually impairment describe assess impairment exist estimate future cash flow expect result use asset eventual disposal actual outcome vary significantly estimate discount future cash flow factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment pension postemployment benefit group employee participate post employment define benefit plan calculation recognise asset liability plan base statistical actuarial calculation particular present value define benefit obligation impact assumption discount rate arrive present value future pension liability assumption future increase salary benefit furthermore group independent actuary use statistically base assumption cover area future withdrawal participant plan estimate life expectancy december present value group define benefit obligation million swiss franc fund plan million swiss franc unfunded plan note actuarial assumption differ materially actual result change market economic condition high low withdrawal rate long short life span participant change factor assess difference impact asset liability recognise balance sheet future period legal provision group company party legal proceeding significant matter describe note legal provision december total million swiss franc asdisclosed note additional claim cover exist provision insurance assurance increase scope matter future lawsuit claim proceeding investigation material change arise impact provision recognise balance sheet future period environmental provision group provision environmental remediation cost december total million swiss franc disclose note material component environmental provision consist cost fully clean refurbish contaminate site treat contain contamination certain site future remediation expense affect number uncertainty include limited detection previously unknown contaminate site method extent remediation percentage waste material attributable group remediation site relative attributable party financial capability potentially responsible party management believe total provision environmental matter adequate base currently available information give inherent difficulty estimate liability area guarantee additional cost incur amount accrue effect resolution environmental matter result operation predict uncertainty concern time future expenditure result future operation change arise impact provision recognise balance sheet future period finance report roche group note roche group consolidate financial statement income taxis december net liability current income taxis million swiss franc net liability defer income taxis million swiss franc disclose note significant estimate require determine current defer asset liability income taxis estimate base interpretation exist tax law regulation management believe estimate reasonable recognise liability income taxrelate uncertainty adequate internal external factor favourable unfavourable effect income tax asset liability factor include limited change tax law regulation andor rate change interpretation exist tax law regulation future level spending change overall level pretax earning change arise impact asset liability recognise balance sheet future period change accounting policy late international accounting standard board iasb publish revise version ia financial instrument disclosure presentation revise version ia financial instrument recognition measurement improvement international accounting standard make change exist standard quarter iasb publish ifrs sharebase payment ifrs business combination ifrs insurance contract ifrs noncurrent asset hold sale discontinue operation revise version ias impairment asset ias intangible asset amendment ias mid iasb issue revision ias fair value option group adopt effective january description change effect consolidated financial statement give ias accounting policy change accounting estimate error matter revise standard require change accounting policy arise application new revise standard interpretation apply retrospectively specify transitional requirement particular standard interpretation previously group apply change prospectively specify transitional requirement retrospective application require result comparative period opening balance period restate new accounting policy apply prospective application require new accounting policy apply result current period comparative period restate ifrs sharebased payment matter new standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement head group previous policy expense record equitysettle equity compensation plan expense cashsettle equity compensation plan record base intrinsic value outstanding obligation operating expense standard require retrospective application certain transitional requirement transitional requirement require company apply new standard retrospective effect award november vest december additionally cashsettle award exercise december apply transitional requirement pretax expense million swiss franc record million swiss franc restate result impact transitional requirement amount indicative future expense plan expense cashsettle plan total million swiss franc reclassify operating expense impact application ifrs restate operating result million chf retrospective previously report impact application operating restate ifrs expense result cost sale marketing distribution research development general administration total operate expense finance report roche group note roche group consolidate financial statement addition amount expense total million swiss franc roche connect roche performance share plan include operating result originally publish need restate new standard affect group effective tax rate defer tax record base expect tax benefit arise vest awards united states tax jurisdiction current equity price input calculation impact income statement income tax benefit cap reference ifrs pretax expense excess recognise directly equity information group equity compensation plan give note ifrs business combination matter new standard require amortisation goodwill cease date implementation goodwill continue test impairment standard require prospective application standard apply goodwill amortisation expense million swiss franc continue business million swiss franc discontinue business record additional impairment necessary addition ia revise intangible asset standard typically result intangible asset recognise acquisition previously consequently goodwill arise new standard affect group effective tax rate tax benefit record respect goodwill amortisation base group result group effective tax rate expect decrease percentage point ia revise intangible asset matter revise standard typically result intangible asset recognise inlicense arrangement similar research development alliance previously expenditure record research development expense revise standard require prospective application ias revise ias revise financial instrument group fully apply previous ias ias financial instrument revise standard significant effect group result financial position matter revise standard require significant orprolonge decline fair value availableforsale financial asset consider objective evidence impairment group previous accounting policy decline fair value availableforsale financial asset consider objective evidence impairment decline significant prolong consequently revise standard typically result impairment charge recognise available forsale financial asset early stage previous accounting policy additionally group adopt revision ias fair value option group debt instrument asspecifie note designate fairvaluethroughprofitorloss previously subject qualify fair value hedge designation fairvaluethroughprofitorloss result relevant information eliminate significantly reduce measurement recognition inconsistency revise standard require retrospective application additionally result restatement equity conversion element certain group convertible debt instrument result equity january reduce million swiss franc additional pretax income million swiss franc record restate result ias revise presentation financial statement matter revise standard require presentation result discontinue business single face income statement additionally revise standard require minority interest include group equity separate category balance sheet addition revise standard permit separate presentation statement recognise income expense statement transaction equity holder acting capacity equity holder finance report roche group note roche group consolidate financial statement presentation income statement new revise standard result significant change format content income statement addition group certain presentational change improve comparability result healthcare company allow reader accurate assessment sustainable earning capacity group change apply retrospectively list royalty operating income show separate line sale cost sale include royalty expense directly link good sell million swiss franc million swiss franc operating expense remove income statement administration expand general administration additionally include operating expense royalty expense include cost sale financial income financing cost disclose separately face income statement capital taxis report general administration instead financial income previously million swiss franc million swiss franc include corporate business segment restate income statement year end december million chf originally discontinue ias group publish business ifrs ia change restate sale operating item operating profit financial nonoperate item profit taxis income taxis profit continue business profit discontinued business net income attributable roche shareholder minority interest earning share nonvoting equity security dilute group chf presentation balance sheet balance sheet december restate follow change ifrs adopt effective january result implementation ifrs net asset december million swiss franc higher consist inventory million swiss franc asset defer tax asset million swiss franc asset liability cashsettle equity compensation plan million swiss franc liability result implementation ias revise ias revise net asset december million swiss franc lower consist longterm debt million swiss franc liability defer tax asset million swiss franc asset addition provision sale return sale chargeback classify provision accrue liability respectively previously report account receivable reclassification appropriately present balance december balance sheet total million swiss franc reclassify account receivable provisionscurrent million swiss franc accrue liability million swiss franc impact net income equity reclassification finance report roche group note roche group consolidate financial statement restate balance sheet december millions chf originally ias ias group publish revise ifrs ia change restate noncurrent asset current asset total asset noncurrent liability current liability total liability total net asset minority interest equity presentation change equity new revise standard result significant change format content change equity particular ias revise permit separate presentation statement recognise income expense statement transaction equity holder acting capacity equity holder addition group certain presentational change order fairly present group financial position change apply retrospectively list result implementation ia revise ifrs net accounting effect genentech chugai stock repurchase stock option record equity allocate retain earning minority interest base relevant ownership percentage previously entry record minority interest standard require retrospective application accordingly million swiss franc reclassify minority interest retain earning january equity element arise issue convertible debt show retain earning separate reserve accordingly million swiss franc reclassify retain earning january restate equity january millions chf originally ias ias group publish revise ifrs ia change restate share capital equity instrument retain earning fair value reserve hedging reserve translation reserve equity conversion reserve equity attributable roche shareholder minority interest total equity total impact change accounting policy equity million swiss franc negative million swiss franc attributable roche shareholder million swiss franc attributable minority interest finance report roche group note roche group consolidate financial statement group currently assess potential impact new revise standard effective january effective january group apply ias revise employee benefit matter revise standard allow actuarial gain loss define benefit plan record directly equity case adjustment arise limit recognition asset define benefit plan record directly equity revise standard require retrospective application group estimate restate result profit tax approximately million swiss franc high net income approximately million swiss franc high equity december approximately billion swiss franc low group expect new revise standard interpretation significant effect group result financial position expand disclosure certain area notably ifrs financial instrument disclosure group implement financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie group subsidiarie genentech chugai treasury operation operational independence whilst work financial risk management framework consistent rest group information financial risk available annual report genentech chugai financial risk management group govern policy guideline approve senior management policy guideline cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy guideline cover area cash management investment excess fund raise short longterm debt compliance policy guideline manage segregated function group objective financial risk management contain deem appropriate exposure type financial risk mention order limit negative impact group result financial position group actively measure monitor manage financial risk exposure function pursuant segregation duty principle accordance financial risk policy group manage market risk exposure use financial instrument derivative deem appropriate group policy practice enter derivative transaction trade speculative purpose purpose unrelated underlying business foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc group actively monitor currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract foreign exchange option crosscurrency swap hedge certain commit anticipate foreign exchange flow financing transaction transaction exposure arise local currency pay receive transaction denominate foreign currency vary change exchange rate group company revenue operating expense primarily local currency similarly transaction exposure arise net balance monetary asset hold foreign currency local level group company manage exposure necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure monthly basis finance report roche group note roche group consolidate financial statement translation exposure arise consolidation foreign currency denominate financial statement group foreign subsidiary effect group consolidated equity show currency translation movement group partially hedge net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regularly significant group cash outflow research development production administration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc relative currency adverse impact consolidate net income similarly relative decrease value swiss franc favourable effect result report swiss franc interest rate risk interest rate risk arise movement interest rate effect group net income financial position change interest rate cause variation interest income expense result interestbeare asset liability addition affect market value certain financial asset liability instrument describe follow section market risk financial asset interest rate group major debt instrument fix describe note group use interest rate derivative manage interest rate risk market risk financial asset change market value certain financial asset derivative instrument affect net income financial position group financial longterm asset hold strategic purpose marketable security hold fund management purpose risk loss value manage review prior invest continuous monitoring performance investment change risk profile investment equity bond debenture fix income instrument enter basis guideline regard liquidity credit rating credit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure significant concentration trade receivables counterparty credit risk group large number customer wide geographical spread credit exposure critical country group obtain credit insurance country risk limit exposure continuously monitor exposure financial asset credit risk control set policy limit credit exposure highquality counterpartie regular review credit rating set define limit individual counterparty appropriate reduce exposure netting agreement isda international swap derivative association master agreement sign respective counterpartie maximum exposure credit risk result financial activity consider net agreement equal carrying financial asset plus positive fair value derivative instrument credit exposure diversify different counterpartie liquidity risk group company need sufficient availability cash meet obligation individual company generally responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group give ability efficiently use international capital market financing purpose syndicate credit facility billion euro establish term seven year facility utilise finance report roche group note roche group consolidate financial statement segment information divisional information millions chf roche pharmaceutical genentech chugai segment revenue segment revenuesdivisional sale interdivisional sale divisional sale party segment result operate profit exceptional item amortisation goodwill major legal case change group organisation segment resultsoperate profit segment asset liabilitie divisional asset segment asset segment asset nonsegment asset total asset divisional liability segment liability segment liability nonsegment liability total liability segmental expense information research development cost equity compensation plan expense restructuring expense capital expenditure acquisition addition property plant equipment addition intangible asset total capital expenditure segment information depreciation property plant equipment amortisation intangible asset impairment property plant equipment impairment goodwill impairment intangible asset income associate company investment associate company finance report roche group note roche group consolidate financial statement pharmaceutical diagnostic division division corporate group finance report roche group note roche group consolidate financial statement information geographical segmentin millions chf sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total genentech effective september group acquire majority interest approximately genentech inc biotechnology company united states june group exercise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock reduce group majority interest genentech issue additional share common stock connection equity compensation plan issue additional share purpose affect group percentage ownership interest affiliation agreement group genentech provide thing genentech establish stock repurchase programme maintain group percentage ownership interest genentech finance report roche group note roche group consolidate financial statement group ownership genentech decrease conversion redemption lyon dollar exchangeable note describe note change group ownership occur stock repurchase genentech exercise stock option genentech employee effective april genentech implement twoforone share split genentech common stock form stock dividend impact group percentage ownership genentech group consolidated result december group interest genentech common stock genentech publicly trade list new york stock exchange symbol dna genentech prepare financial statement conformity accounting principle generally accept united states gaap file quarterly basis securities exchange commission sec difference ifrs gaap certain consolidation entry difference requirement international financial reporting standard ifrs gaap difference genentech standalone financial result gaap basis financial result genentech consolidate roche group accordance withifrs reconciliation genentech result usd chf usd chf million million million million operate margin gaap basis redemption cost special litigation item operate margin nonus gaap basis add deduct difference consolidation entry add redemption cost expense equity compensation plan difference consolidation entry operating profit exceptional item ifrs basis add deduct exceptional item amortisation goodwill segment resultoperate profit ifrs basis add deduct nonoperate item ifrs basis financial income financing cost income taxis net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis translate usd chf usd chf effective january group adopt ifrs sharebase payment ifrs financial statement matter new standard require fair value equity compensation plan award employee estimate grant date record expense vest period expense charge appropriate income statement head standard require retrospective application certain transitional requirement apply transitional requirement pretax expense million dollar million swiss franc relate plan genentech record restate million dollar million swiss franc impact transitional requirement amount indicative future expense plan finance report roche group note roche group consolidate financial statement genentech gaap financial statement currently expense record plan genentech adopt statement financial accounting standard sharebase payment fas effective january matter require company report gaap recognise compensation expense plan different date application measurement requirement transitional arrangement fas ifrs expense record genentech gaap financial statement equity compensation plan expense record roche group ifrs financial statement plan difference ifrs gaap relatively minor impact genentech stock repurchase june genentechs board director authorise extension current stock repurchase programme repurchase billion dollar genentechs common stock june initially december genentechs board director authorise stock repurchase programme repurchase billion dollar genentechs common stock extend additional billion dollar september genentech repurchase common stock worth million dollar million swiss franc million dollar million swiss franc oceanside biologics manufacturing facility june genentech complete purchase oceanside biologic manufacturing facility sandiego california biogen idec purchase cost include closing cost million swiss franc genentech senior note july genentech complete private placement billion dollar aggregate principal year year year senior note placement consist million dollar senior note billion dollar senior note million dollar senior note genentech intend use proceed reduction repayment certain lease arrangement fund future capital expenditure include upgrade startup validation cost oceanside general corporate purpose detail give note genentech lease quarter genentech pay million dollar buy finance lease obligation respect manufacturing facility vacaville california certain building south san francisco site carry value obligation december million dollar million swiss franc december genentech enter master lease agreement slough ssf llc lease property adjacent genentechs south san francisco site lease place phase phase building lease begin phase building lease begin early ifrs lease account finance lease genentech expect completion project total spending own improvement lease asset excess million dollar total lease payment contemplate master lease agreement currently estimate million dollar matter detail genentech legal case give note detail genentechs equity compensation plan give note chugai effective october roche group chugai complete alliance create lead research drive japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai fully consolidated subsidiary group december group interest chugai finance report roche group note roche group consolidate financial statement common stock chugai publicly trade list tokyo stock exchange stock code tse chugai prepare financial statement conformity accounting principle generally accept japan jgaap file quarterly basis tokyo stock exchange difference ifrs jgaap certain consolidation entry difference requirement international financial reporting standard ifrs jgaap difference chugais standalone financial result jgaap basis financial result chugai consolidated roche group accordance ifrs acquire roche interest chugai treat acquisition ifrs jgaap alliance treat merger chugai nippon roche jgaap result chugai include goodwill fair value adjustment record roche result quantify table acquisition accounting include roche fair value adjustment impact net income need add minority interest calculation roche ifrs result roche ifrs result depreciation property plant equipment calculate straightline method chugais jgaap result reduce balance method additionally certain income expense notably restructure cost require jgaap report extraordinary item chugais jgaap result extraordinary item report operate profit line roche ifrs result item normally include operating profit treat extraordinary exceptional item restructure cost million swiss franc million swiss franc difference ifrs jgaap relatively minor impact reconciliation chugai result million chf chugai operating profit exceptional item acquisition accounting impact ifrs basis depreciation property plant equipment amortisation acquisitionrelate intangible asset chugai operate profit exceptional item ifrs basis add deduct exceptional item amortisation goodwill chugai segment resultoperate profit ifrs basis add deduct corporate chugai otc nonoperate item ifrs basis gain settlement define benefit plan financial income financing cost chugai otc income taxis net income ifrs basis minority interest calculation add acquisition accounting impact net income net income exclude acquisition accounting minority interest percentage average year income applicable minority interest ifrs basis translate jpy chf jpy chf dividend dividend distribute party hold chugai share total million japanese yen million swiss franc million japanese yen million swiss franc record minority interest note dividend pay chugai roche eliminate consolidation intercompany item finance report roche group note roche group consolidate financial statement restructure production facility february chugai announce restructure production facility exist plant integrate facility year restructure plant kagamiishi sell half total restructuring cost include loss disposal kagamiishi plant million swiss franc show extraordinary loss chugais jgaap financial statement pension postemployment benefit second half chugai return employee pension fund japanese government result settlement gain million swiss franc accordance group management organisational structure report general administration expense corporate business segment show extraordinary gain chugais jgaap financial statement chugai otc effective december chugai sell otc business lion corporation pretax gain disposal million swiss franc record result chugais otc business include profit discontinue business note early retirement programme chugai announce early retirement programme retirement date september end application period august total employee apply programme restructuring cost billion japanese yen million swiss franc record programme show extraordinary loss chugais jgaap financial statement share repurchase chugai repurchase common share total consideration billion japanese yen million swiss franc result group ownership chugai increase share repurchase chugai convertible bond detail series chugai pharmaceutical unsecured convertible bond include conversion year give note royalty operating income royalty operating income millions chf royalty income income outlicense agreement gain disposal product total royalty operating income royalty income royalty income pharmaceutical division million swiss franc million swiss franc diagnostic division million swiss franc million swiss franc income outlicense agreement certain group company receive party upfront milestone similar nonrefundable payment relate sale licensing product technology revenue associate performance milestone recognise base achievement milestone define respective agreement revenue nonrefundable upfront payment licence fee initially report deferred income recognise income earn period development collaboration manufacturing obligation finance report roche group note roche group consolidate financial statement gain disposal product continuous realignment product portfolio group periodically dispose product line long consider core product priority product development portfolio proceed reinveste group inlicense arrangement research development alliance collaboration february group announce sale exclusive rights soriatane connetic corporation cash receive million swiss franc august group agree license sell certain patent right patent portfolio party cash receive million swiss franc disposal product concern book value gain disposal cash proceed disposal report segment result roche pharmaceutical business segment major legal case income expense major legal case million chf roche pharmaceutical legal case genentech legal case diagnostic legal case total income expense roche pharmaceutical legal case roche diagnostic gmbh rdg smithkline beecham cork ltd party arbitration concern rdgs termination carvedilol license agreement amend relate licensing comarkete carvedilol rdg submit claim damage arbitration tribunal zurich submit counterclaim assert invalidity rdgs termination claim damage base development current arbitration settlement negotiation group increase exist provision million swiss franc additional expense record roche pharmaceutical segment result disclose separately income statement materiality order fairly present group result total provision record rdg disclose seriously prejudice rdgs position matter genentech legal case june genentech announce los angeles county superior court jury vote award city hope medical center city hope approximately million dollar compensatory damage base find breach agreement genentech city hope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal october court appeal affirm verdict damage award respect october genentech announce seek review california supreme court discretion case review november genentech file petition review california supreme court february california supreme court grant petition provision classify longterm record damage award appeal process interest accrue total damage simple annual rate follow judgement interest million swiss franc million swiss franc record time cost provision financing cost october genentech enter arrangement thirdparty insurance company post surety bond million dollar connection judgement arrangement genentech pledge million dollar cash investment secure bond thiswas increase million dollar million dollar million dollar million dollar million swiss franc report restrict cash financial longterm asset note consolidated financial statement approve prior february decision california supreme court refer provision restrict cash respect litigation classify current follow february decision reclassify financial statement current noncurrent resolution matter expect year comparative information restate finance report roche group note roche group consolidate financial statement august united states patent trademark office declare interference chiron patent patent application exclusively license genentech university pennsylvania relate antiher antibody declare interference patent trademark office determine substantial question inventor chiron patent invent technology involve entitle patent subsequently patent trademark office redeclare interference include addition abovereference chiron patent university patent application number patent patent application own chiron genentech include chiron patent issue second patent infringement lawsuit file march genentech chiron november patent trademark office issue ruling preliminary motion ruling terminate interference involve patent application reference genentech license university redeclare interference genentech chiron patent patent application determination affect validity genentech chiron patent patent application involve remain interference january genentech file notice appeal court appeal federal circuit june genentech chiron agree settlement interference proceeding october genentech receive subpoena united states department justice request document relate promotion rituxan prescription product approve treatment relapse refractory lowgrade follicular cdpositive bcell nonhodgkin lymphoma genentech cooperating associate investigation genentech advise civil criminal nature potential outcome matter determine time request file party reexamination patent cabilly patent coowne genentech city hope july patent trademark office order reexamination patent september patent trademark office issue aninitial nonfinaloffice action reject claim patent action routine expect step reexamination procedure reexamination process ongoing final outcome matter determined time second reexamination request patent file december party patent trademark office take action respect additional request cabilly patent expire relate method genentech certain antibody antibody fragment cell dna method genentech license cabilly patent company derive significant royalty licence claim cabilly patent remain valid enforceable reexamination process july genentech employee employment end april file nonpublic qui tam complaint seal united states district court district maine genentech biogen idec allege violation false claim act retaliatory discharge employment december usfederal government file notice election decline intervention lawsuit complaint subsequently unseal genentech serve january genentech evaluating complaint thepotential outcome determine time genentech annual report quarterly sec filing contain detailed disclosure litigation matter require gaap include detail matter include information litigation currently significant matter refer diagnostic legal case provision certain litigation arbitration matter diagnostic division increase million swiss franc provision record base current litigation settlement negotiation recent settlement agreement additional expense disclose separately income statement duetothe materiality order fairly present group result payment total million swiss franc finance report roche group note roche group consolidate financial statement october applera corporation applera file suit group superior court california file notice arbitration american arbitration association superior court lawsuit arbitration demand claim concern interpretation enforcement contract group applera commercialisation polymerase chain reaction pcr technology claim seek termination certain contract declaration right obligation contract monetary damage relief unspecified allege breach agreement party december group file response arbitration proceeding thesame day group respond appleras complaint superior court proceeding petitioning court compel arbitration claim allege applera stay lawsuit pende completion arbitration october court appeal state california rule petition compel arbitration grant remand case superior court direction grant petition group announce settlement agreement reach applera regard outstanding litigation arbitration relate contractual relationship involve right commercialisation polymerase chain reaction pcr technology group file suit promega corporation promega allege patent infringement breach licence agreement relate polymerase chain reaction pcr technology district court northern district california decide patent concern unenforceable reject breach licence claim november group notify promega file nonpublic qui tam action group district court eastern district west virginia march complaint file false claim act allege federal government overcharge purchase pcr enzyme product july federal government notify court decision intervene promegas complaint november court order complaint unseal group file motion dismiss complaint august court dismiss complaint prejudice september group announce settlement agreement reach promega regard outstanding litigation relate polymerase chain reaction pcr technology change group organisation list major group subsidiary associate company include note discontinued business discuss note gain loss change group organisation millions chf consumer health otc business gain loss disposal attributable roche pharmaceutical business total net cash flow change group organisation millions chf acquisition glycart igen acquisition total cash flow acquisition subsidiary associate company divestment consumer health otc business divestment total cash flow divestment discontinue business subsidiary associate company amount net cash balance acquireddiveste companybusiness finance report roche group note roche group consolidate financial statement acquisition glycart effective july group acquire control interest glycart biotechnology ltd glycart privately own biotechnology research company base schlieren zurich switzerland glycart report roche pharmaceutical business segment purchase consideration pay million swiss franc allocate follow glycart acquisition net asset acquire millions chf carrying value carry value prior acquisition acquisition goodwill intangible asset inprocess research development intangible asset core technology property plant equipment defer income taxis cash net asset liability total goodwill recognise result premium pay acquisition represent synergy obtain group exist business utilise acquire core technology intangible asset core technology amortise straightline basis year begin august intangible asset inprocess research development amortise useful life straightline basis beginning point available use subsequent acquisition glycart contribute net expense million swiss franc roche pharmaceutical business result glycart acquire january revenue group unchanged group net income lower million swiss franc compare report result acquisition igen february group acquire control interest igen international inc igen apublic company headquartered gaithersburg maryland usa acquisition give group broad access human invitro diagnostic immunochemistry sector use electrochemiluminiscence ecl technology development elecsys product line acquisition approve extraordinary general meeting igen shareholders february clear relevant antitrust authority allocation total purchase consideration million swiss franc follow igen acquisition net asset acquire millions chf goodwill intangible asset defer income taxis cash net asset liability total intangible asset amortise straightline basis year begin march finance report roche group note roche group consolidate financial statement financial income financing cost financial income million chf year end december gain sale equity security loss sale equity security dividend income gain loss equity derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security writedown impairment longterm loan net interest income income debt security foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense total financial income financing cost million chf year end december interest expense amortisation discount debt instrument gain loss interest rate derivative net time cost provision total financing cost financing cost include net gain financial liability fairvaluethroughprofitorloss million swiss franc net loss million swiss franc include gain loss interest rate derivative net include change fair value attributable change liabilitie credit risk component change fair value credit risk calculate compare difference present value future cash flow bond discount swap libor yield curve market price bond decrease credit spread relative swap yield curve credit risk component result loss million swiss franc gain million swiss franc cumulative change fair value attributable change credit risk issuance instrument gain million swiss franc interest expense liability fairvaluethroughprofitorloss million swiss franc million swiss franc exceptional income bond conversion redemption group convert redeem certain debt instrument debt reduce million swiss franc total cash outflow million swiss franc net pretax gain million swiss franc result show net gain disclose separately income statement materiality gain order fairly present group result detail give note finance report roche group note roche group consolidated financial statement impact bond conversion redemption millions chf exceptional income bond conversion increase redemption reduction pretax debt cash outflow lyon dollar exchangeable note lyon iii dollar exchangeable note chameleon dollar bond lyon dollar exchangeable note limited conversion prefer stock total income taxis income tax expense millions chf current income taxis adjustment recognise current tax prior period defer income taxis total charge income taxis group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate million chf average expect tax rate tax effect utilisation previously unrecognise tax loss nontaxable incomenondeductible expense difference continue business exceptional item effective tax rate profit income tax profit income tax tax taxis rate tax taxis rate roche exclude genentech chugai genentech chugai continue business exceptional item effective tax rate amortisation goodwill major legal case change group organisation exceptional income bond conversion redemption group effective tax rate finance report roche group note roche group consolidate financial statement income tax asset liability millions chf current income taxis current income tax asset current income tax liability net current income tax asset liability defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability defer income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance million swiss franc million swiss franc million swiss franc expire yearsand million swiss franc expire year remain million swiss franc loss expire year defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item defer income taxis movement recognise net asset liability millions chf property plant equipment restructure temporary intangible asset provision difference total year end december net defer income tax asset liability january previously report change accounting policy net defer income tax asset liability january restate charge credit income statement charge credit equity recognise gain loss charge credit equity equity compensation plans transaction shareholder acquisition igen discontinue business currency translation effect net defer income tax asset liability december finance report roche group note roche group consolidate financial statement property plant equipment restructure temporary intangible asset provision difference total year end december net defer income tax asset liability january charge credit income statement charge credit equity recognise gain loss charge credit equity equity compensation plan transaction shareholder acquisition glycart currency translation effect net defer income tax asset liability december discontinue business profit discontinued business million chf consumer vitamin consumer vitamin health fine health fine otc chemical total otc chemical total segment revenue expense operate profit exceptional item amortisation goodwill operating profit financing cost profit taxis income taxis business result gain loss disposal income taxis profit disposal profit discontinue business earning share nonvoting equity security discontinue business chf basic diluted equivalent amount chf chf respectively asset liability discontinue business million chf consumer vitamin consumer vitamin health fine health fine otc chemical total otc chemical total property plant equipment longterm asset current asset total asset provision noncurrent liability current liability total liability net asset finance report roche group note roche group consolidate financial statement significant cash flow discontinue business million chf consumer vitamin consumer vitamin health fine health fine otc chemical total otc chemical total operating cash flow major legal case proceed disposal total significant cash inflow outflow divestment consumer health otc business july group announce sale roche consumer health global otc overthecounter medicine business bayer group sale include production facility belong roche pharmaceutical business agreement bayer majority local business transfer bayer end december divestment bayer complete measure interm roche consumer health sale party divestment remain complete term agreement majority cash proceed total million swiss franc transfer group january addition group receive million swiss franc remain divestment complete july chugai announce sale otc business lion corporation sale complete effective december result consumer health otc business show result include remain roche consumer health transfer bayer result include consumer health otc business period gain disposal consumer health otc business roche pharmaceutical production facility millions chf net proceed incidental transaction cost net asset dispose impairment restructuring charge accrual residual obligation retain roche group gain disposal discontinue business consumer health otc business roche pharmaceutical business segment gain disposal table figure include preliminary assessment net debt adjustment purchase price mechanism initial calculation impairment restructuring charge accrual residual obligation retain roche group cash inflow disposal million swiss franc net cash balance million swiss franc hold company consumer health otc business cash payment transaction cost million swiss franc term agreement majority cash proceed total million swiss franc transfer group january show receivable december balance sheet cash inflow disposal total million swissfranc consist million franc receive bayer january additional million swiss franc receive part business sell bayer finance report roche group note roche group consolidate financial statement continue business roche pharmaceutical business segment production facility include sale bayer show roche pharmaceutical result date disposal production facility transfer bayer end include december balance sheet connection divestment roche consumer health roche pharmaceutical business reassess utilisation manufacturing facility infrastructure service capacity addition term agreement bayer roche pharmaceutical business agree certain interim manufacturing service obligation bayer result roche pharmaceutical business record impairment charge base estimate net selling price show table bayer transaction impact roche pharmaceutical business segment millions chf net proceed incidental transaction cost net asset production facility impairment charge restructure charge accrual residual obligation retain roche pharmaceutical business gain loss disposal roche pharmaceutical business segment divestment vitamin fine chemical business effective september receive final regulatory approval group complete sale global vitamin fine chemical business vfc business dutch company dsm term final purchase agreement dsm certain agree purchase price adjustment mechanism final amount arise mechanism approve group dsm additional cash transfer group dsm additional amount record follow sale vfc business certain asset liability vitamin fine chemical division mainly associate vitamin case remain group describe section vitamin case addition group give dsm certain indemnity respect remedial action site vfc business require environmental law arrangement place utilisation certain asset certain purchasing contract adopt dsm preferred supplier pharmaceutical ingredient arrangement group guarantee purchase period year begin january product sale value total million euro group reimburse dsm unutilised amount arrangement consist certain residual obligation fully accrue expense million swiss franc record million swiss franc represent aftertax amortisation discount liability vitamin case follow settlement agreement department justice pricing practice vitamin market overall settlement agreement class action suit bring buyer bulk vitamin group record provision respect vitamin case provision group well estimate time total liability arise take account currency movement time value money provision legal fee record separately group record additional provision base development litigation settlement negotiation europe finance report roche group note roche group consolidate financial statement january district columbia circuit court appeals rule class action litigation bring behalf nonus purchaser bulk vitamin group manufacturer nonus plaintiff bring claim court antitrust law allege damage suffer transaction outside united states june supreme court united states nullify decision district columbia circuit court appeal supreme court remand case low court review alternative argument permit claim proceed united states remand june panel district columbia circuit court appeal rule unanimously court jurisdiction plaintiff claim affirm initial dismissal complaint october plaintiff petition supreme court discretionary review january supreme court issue order deny plaintiff petition plaintiff day date order seek reconsideration provision record respect litigation group anticipate unfavourable outcome total payment year million swiss franc million swiss franc charge provision previously record group seek resolve remain outstanding issue time final amount involve uncertain remain provision record total million swiss franc base current litigation recent settlement agreement provision consider shortterm cash outflow expect arise discount time value money consider material case litigation negotiation progress possible ultimate liability different provision currently record divestment vfc business liability respect vitamin case discuss remain roche group roche dsm sign indemnity cooperation agreement roche provide dsm certain indemnity guarantee connection vitamin case employee benefit employee remuneration million chf wage salary social security cost postemployment benefit define benefit plan postemployment benefit define contribution plan equity compensation plan employee benefit total employee remuneration charge employee benefit include relevant expenditure line function employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit finance report roche group note roche group consolidate financial statement pension postemployment benefit employee cover retirement benefit plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic condition country employee employ major plan define benefit plan large locate switzerland united states germany united kingdom japan postemployment benefit consist postretirement healthcare life insurance scheme principally united states plan usually fund payment group employee trust independent group finance plan unfunded notably major define benefit plan germany liability obligation record group balance sheet define benefit plan expense recognise millions chf current service cost interest cost expect return plan asset net actuarial gain loss recognise past service cost gain loss curtailment gain loss settlement limit asset recognition total include employee remuneration actual return plan asset million swiss franc million swiss franc disclose note second half chugai return employee pension fund japanese government result settlement gain million swiss franc accordance group management organisational structure report general administration expense corporate business segment effective january group apply ias revise employee benefit matter therevise standard allow actuarial gain loss define benefit plan record directly equity case adjustment arise limit recognition asset define benefit plan record directly equity revise standard require retrospective application consequently group estimate restate result pretax expense include employee remuneration approximately million swiss franc low million swiss franc relate continue business million swiss franc relate discontinued business define benefit plan movement net recognise asset liability millions chf january consumer health otc business total expense include employee remuneration contribution pay benefit pay unfunded plan currency translation effect december december group pay additional contribution million swiss franc swiss post employment define benefit plan payment include contribution pay table account recognise surplus fund pension plan group consolidate financial statement include actuarial calculation group pension expense balances finance report roche group note roche group consolidate financial statement define benefit plan amount recognise balance sheet million chf fund plan present value fund define benefit obligation plan asset hold trust fair value plan asset excess deficit present value obligation unrecognise actuarial gain loss unrecognise past service cost net recognise asset liability fund define benefit obligation unfunded plan present value unfunded define benefit obligation unrecognise actuarial gain loss unrecognise past service cost recognise liability unfunded define benefit obligation total net recognise asset liability fund unfunded define benefit obligation report surplus recognise noncurrent asset deficit recognise noncurrent liability total net recognise asset liability amount include nonpension postemployment benefit scheme principally medical plan show postemployment benefit plan millions chf present value define benefit obligation plan asset hold trust fair value plan asset excess deficit present value obligation unrecognised actuarial gain loss net recognise asset liability amount recognise balance sheet postemployment define benefit plan predominantly non current report noncurrent asset liability include fair value asset fund plan zero group nonvoting equity security write option total fair value million swiss franc zero group operate define benefit scheme country actuarial assumption vary base local economic social condition range assumption actuarial valuation significant define benefit plan country stable currency interest rate show define benefit plan actuarial assumption weight weight average range average range discount rate project rate remuneration growth expect rate return plan asset healthcare cost trend rate finance report roche group note roche group consolidated financial statement employee stock option equity compensation benefit group operate equity compensation plan include separate plan genentech chugai effective january group adopt ifrs sharebased payment matter new standard require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense charge appropriate income statement head standard require retrospective application certain transitional requirement detail give note expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operate expense share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche performance share plan roche stock appreciation right total equity compensation plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf share option plan roche option plan genentech stock option plan chugai stock acquisition right total share option plan equity compensation plan roche connect genentech employee stock purchase program roche stocksettle stock appreciation right roche performance share plan roche stock appreciation right total equity compensation plan total cash inflow outflow equitysettle cashsettle finance report roche group note roche group consolidate financial statement roche longterm group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan share option plan roche option plan award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equitysettle award sevenyear duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note introduction roche longterm number option grant roche option plan significantly reduce eligible employee receive roche stocksettle stock appreciation right instead roche option plan movement number option outstanding number weight average number weight average option exercise price chf option exercise price chf outstanding january grant forfeit exercise expired outstanding december exercisable roche option plan term option outstanding december option outstanding option exercisable weighted weighted weight average average average number year remain exercise number exercise year grant outstanding contractual life price chf exercisable price chf total genentech stock option plan genentech stock option plan adopt amend april genentechs shareholder approve equity incentive plan plan allow grant stock option incentive stock option stock purchase right employee director consultant genentech incentive stock option stock purchase right grant plan date option grant nontradable equitysettle award tenyear duration vest phase basis year subject continued employment genentech stock option plan movement number option outstanding number number option weight average option weight average thousand exercise price usd thousand exercise price usd outstanding january grant forfeit exercise expired outstanding december exercisable finance report roche group note roche group consolidate financial statement genentech stock option plan term option outstanding december option outstanding option exercisable weighted weight number weight average average number average range exercise price outstanding year remain exercise exercisable exercise usd thousand contractual life price usd thousand price usd total chugai stock acquisition right chugai adopt stock acquisition right programme programme allow grant right employee director chugai right entitle holder purchase chugai share specify exercise price option nontradable equitysettle award tenyear duration vest immediately grant chugai stock acquisition right movement number right outstanding number weight average number weight average option exercise price jpy option exercise price jpy outstanding january grant forfeit exercise expired outstanding december exercisable chugai stock acquisition right term right outstanding december right outstanding right exercisable weighted weighted weight average average average number year remain exercise number exercise year grant outstanding contractual life price jpy exercisable price jpy total finance report roche group note roche group consolidate financial statement issue share option issue share option include methodology calculate fair value main input valuation model describe issue share option plan roche genentech stock chugai stock option plan option plan acquisition right number option grant underlying equity roche nonvoting genentech common chugai share equity security stock block currency swiss franc dollar japanese yen vest period progressively progressively immediate year year contractual life year year year weight average fair value option issue option pricing model binomial binomial binomial input option pricing model share price grant date exercise price expect volatility expect dividend yield early exercise factor expect exit rate volatility determine reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour chugai grant assume award hold term length previously issue option exercise early equity compensation plan roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold nonvoting equity security programme operational october year cost plan million swiss franc million swiss franc report relevant expenditure line function genentech employee stock purchase program espp genentech employee stock purchase programme allow employee purchase genentech common stock low market value grant date purchase date total thousand share genentech common stock purchase thousand share result cash inflow million swiss franc million swiss franc year cost plan million swiss franc million swiss franc report relevant expenditure line function roche stocksettle stock appreciation right introduction roche longterm group offer stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date option nontradable equitysettle award seven year duration vest phase basis year subject continued employment group cover obligation purchase nonvoting equity security derivative thereon note finance report roche group note roche group consolidate financial statement roche ssar movement number right outstanding number weight average number weight average right exercise price chf right exercise price chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable weighted weighted weight average average average number year remain exercise number exercise year grant outstanding contractual life price chf exercisable price chf total weight average fair value option grant calculate binomial model input model consistent roche option plan award show previously result weight average fair value right chf give total fair value million swiss franc charge vest period year roche performance share plan group offer future nonvoting equity security award board discretion cash equivalent certain director key senior manager programme establish beginning effect year board approve new threeyear cycle roche performance share plan psp operate nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director cycle total award nontradable equitysettle awards award result zero nonvoting equity security depend achievement performance target allocate recipient february blackout period end weight average fair value option grant calculate monte carlo simulation input parameter model covariance matrix roche individual company peer group base threeyear history riskfree rate valuation take account define rank performance structure determine payout psp result value unit psp cycle chf give total fair value million swiss franc charge vest period year roche stock appreciation right employee certain north american subsidiary group receive stock appreciation right sar compensation sar nontradable cash settle award exercise vest period year cash payment base market price group american depositary receipt adr point ofexercise exceed strike price grant price issuance follow implementation roche longterm group plan award cashsettle sar award roche stock appreciation right millions chf liability december intrinsic value vest right december finance report roche group note roche group consolidate financial statement roche stock appreciation right term right outstanding december right outstanding right exercisable weighted weight average average number exercise number exercise year grant outstanding expiry price usd exercisable price usd total fair value december calculate binomial model input model adr price december usd exercise price give table input consistent roche option plan award show previously property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction improve land ment equipment progress total january cost accumulate depreciation impairment net book value year end december january disposal consumer health otc business addition disposal transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value year end december january glycart acquisition disposal consumer health otc business addition disposal transfer depreciation charge impairment charge currency translation effect december cost accumulate depreciation impairment net book value finance report roche group note roche group consolidated financial statement decrease property plant equipment million swiss franc disposal otc business consist asset transfer business million swiss franc impairment charge million swiss franc note impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor change plan use building machinery equipment closure facility presence absence competition technical obsolescence result shorten useful life impairment leasing arrangement group lessee finance lease december capitalise cost property plant equipment finance lease million swiss franc million swiss franc net book value asset million swiss franc million swiss franc finance lease present value future minimum lease payment millions chf year year year total present value minimum lease payment describe note quarter genentech buy finance lease obligation respect manufacturing facility vacaville california certain building south san francisco site carry value lease obligation december million swiss franc operating lease group company party number operating lease mainly plant machinery include motor vehicle certain shortterm property rental arrangement impose significant restriction group total operating lease rental expense million swiss franc million swiss franc operating lease future minimum payment noncancellable lease million chf year year year total minimum payment lease arrangement group lessor finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease lease income finance lease recognise term lease base effective interest rate method finance lease future minimum lease receipt noncancellable lease millions chf present value future gross investment lease minimum lease payment year year year total unearned finance income unguaranteed residual value net investment lease finance report roche group note roche group consolidate financial statement accumulate allowance uncollectible minimum lease payment million swiss franc zero million swiss franc contingent rent recognise income operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement asset report property plant equipment lease income operating lease recognise lease term straight line basis december machinery equipment original cost million swiss franc net book value million swiss franc lease party future minimum lease payment non cancellable lease total million swiss franc million swiss franc year million swiss franc year million swiss franc year contingent rent recognise income capital commitment group capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc addition december genentech enter master lease agreement lease property south san francisco genentechs aggregate lease payment estimate approximately million dollar goodwill goodwill movement carry value asset millions chf january glycart acquisition igen acquisition acquisition disposal consumer health otc business amortisation charge impairment charge currency translation effect december allocate follow business segmentscashgenerating unit roche pharmaceutical genentech chugai diagnostic total accumulate impairment loss goodwill goodwill arise investment associate company classify investment associate company note effective january group implement ifrs business combination matter new standard require amortisation goodwill cease date implementation goodwill continue test impairment standard require prospective application standard apply goodwill amortisation expense million swiss franc record additional impairment necessary finance report roche group note roche group consolidated financial statement goodwill impairment testing group reportable business segment cashgenerate unit test goodwill pharmaceutical division genentech chugai recoverable base fair value cost sell determined reference publicly quote share price genentech chugai share goodwill roche pharmaceutical business significant comparison group total carrying goodwill diagnostic division recoverable impairment testing base value use cash flow projection base recent business plan approve management assume significant change organisation division include management late estimate sale volume pricing production operating cost reflect past experience project year discount rate base rate derive capital asset pricing model datum swiss capital market include swiss federal government year bond treasury year bond smi index adjust pretax rate management believe reasonably possible change key assumption cause carry value goodwill exceed recoverable intangible asset intangible asset movement carry value asset millions chf patent licence trademark intangible asset acquisition relate total january cost accumulate amortisation impairment net book value year end december january igen acquisition disposal consumer health otc business addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value finance report roche group note roche group consolidate financial statement patent licence trademark intangible asset acquisition relate total year end december january glycart acquisition addition disposal amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate follow business segmentscashgenerating unit roche pharmaceutical genentech chugai diagnostic total include roche pharmaceutical business segment intangible asset carry value million swiss franc remain amortisation period year relate purchase group global rights kytril granisetron smithkline beecham diagnostic business segment include intangible asset carry value million swiss franc remain amortisation period year relate acquisition corangeboehringermannheim intangible asset carry value million swiss franc remain amortisation period year relate acquisition igen group currently internally generate intangible asset development criterion recognition asset meet impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lower anticipate sale product capitalise right result shorten useful life impairment associate company group investment associate company account equity method goodwillarise investment associate company classify investment associate company investment associate company millions chf share net income balance sheet value total investment associate company group major investment associate basilea pharmaceutica ltd tripath imaging inc antisoma plc additional information company give note material transaction group associated company finance report roche group note roche group consolidate financial statement financial longterm asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset prepay employee benefit total longterm asset financial longterm asset hold strategic purpose classify noncurrent available forsale investment mainly equity investment unquote equity investment classify availableforsale generally measure cost fair value measure reliably primarily investment private biotechnology company keep group strategic alliance effort carry value equity investment hold cost million swiss franc million swiss franc effective interest rate heldtomaturity investment loan receivable comprise loan party term year restrict cash include million swiss franc cash investment pledge genentech connection city hope litigation note equivalent classify current asset note inventory inventory million chf raw material supply work process finish good intermediate provision slowmove obsolete inventory total inventory expense relate inventory total million swiss franc million swiss franc million swiss franc expense cost sale million swiss franc million swiss franc relate consumer health otc business expense profit discontinue business million swiss franc account receivable account receivable million chf trade account receivable note receivable provision doubtful account total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc bad debt expense million swiss franc million swiss franc finance report roche group note roche group consolidate financial statement current asset current asset millions chf accrue interest income prepaid expense derivative financial instrument restrict cash receivables total current asset restrict cash include million swiss franc cash investment pledge genentech connection city hope litigation note equivalent classify financial longterm asset note marketable security marketable security millions chf financial asset fairvaluethroughprofitorloss heldfortrade investment bond debenture designate fairvaluethroughprofitorloss bond debenture total financial asset fairvaluethroughprofitorloss availableforsale financial asset share bond debenture money market instrument time account month total availableforsale financial asset total marketable security marketable security hold fund management purpose classify current primarily denominate swiss franc euros dollar pound sterling investment hold strategic purpose classify noncurrent note share consist primarily readily saleable equity security bond debenture millions chf average effective average effective contract maturity interest rate interest rate year year year total bond debenture money market instrument generally fix interest rate range depend currency denominate contract mature year december finance report roche group note roche group consolidate financial statement cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent restrict cash include financial longterm asset note current asset seenote account payable account payable million chf trade account payable taxis payable account payable total account payable accrue current liability accrue current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability derivative financial instrument appropriate circumstance group use derivative financial instrument risk management trading strategy discuss note derivative financial instrument carry fair value themethod determine fair value describe note derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract swap interest rate derivative swap derivative total derivative financial instrument hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement finance report roche group note roche group consolidated financial statement describe note group financial risk management policy foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropriate certain risk alter use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case thehedging instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe genentech hedge fix term debt instrument interest rate swap december instrument designate qualify fair value hedge record balance sheet liability fair value million swiss franc genentech nonus dollar cash flow future royalty income development expense expect year hedge transaction exposure genentech enter derivative financial instrument option forward contract genentech equity investment biotechnology company subject great risk market fluctuation stock market general manage exposure genentech enter derivative financial instrument zero cost collar forward contract december instrument designate qualify hedge accounting record balance sheet fair value million swiss franc matter describe genentech annual report quarterly sec filing movement fair value reserve designate cash flow hedge include note provision contingent liability provision movement recognise liability millions chf environmental legal restructuring provision provision provision total year end december january previously report change accounting policy january restate disposal consumer health otc business vitamin case utilise year provision additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion provision noncurrent portion provision total provision finance report roche group note roche group consolidate financial statement environmental legal restructuring provision provision provision total year end december january vitamin case utilise year major legal case additional provision create utilise year provision additional provision create unused amount reverse utilise year unwind discount currency translation effect december current portion provision noncurrent portion provision total provision expect outflow resource year year year year total provision environmental legal provision provision include million swiss franc million swiss franc environmental matter million swiss franc million swiss franc litigation include major legal case thevitamin case provision environmental matter include separate environmental issue number country approximately half preexist company acquire group nature amount time outflow difficult predict group estimate approximately half provide result cash outflow year significant provision discount legal provision consist mainly major legal case describe note vitamin case describe note amount timing uncertainty outflow discuss note discount rate remain legal provision account balance consist number separate legal matter group company majority cash outflow expect occur year dependent development litigation significant provision discount major legal case describe note vitamin case describe note litigation matter currently significant describe finance report roche group note roche group consolidated financial statement tamiflu development license agreement june gilead sciences inc gilead deliver group notice termination development license agreement tamiflu allege material breach agreement november group gilead sign amend agreement settlement agreement end dispute matter amend agreement include revise calculation royalty payment settlement group pay gilead million dollar retroactive royalty adjustment result cost sale include royalty cost relate tamiflu sale include retroactive adjustment pay november base amend agreement settlement agreement relate sale early general administration expense include million swiss franc retrospective adjustment relate restructure provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group remain amount respect obligation employee arise pharmaceutical division restructure previous restructuring plan timing cash outflow reasonably certain global basis show table significant provision discount provision provision consist claim arise trade provision group company fit category timing cash outflow nature uncertain good estimate show table significant provision discount contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group engage subject physical risk kind nature frequency development event cover insurance effect future operation earning predictable note respect vitamin case note respect major legal case group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define thecollaboration agreement group well estimate future commitment payment million swiss franc million swiss franc million swiss franc noncurrent liability noncurrent liability millions chf defer income longterm liability total noncurrent liability finance report roche group note roche group consolidate financial statement debt debt recognise liability millions chf debt instrument amount bank financial institution capitalise lease obligation borrowing total debt report longterm debt shortterm debt total debt debt repayment term millions chf year year year year year year total debt lyon zero coupon dollar exchangeable note reflect year holder note request group purchase note fair value debt instrument billion swiss franc billion swiss franc fair value total debt billion swiss franc billion swiss franc calculate base observable market price debt instrument present value future cash flows instrument discount market rate interest instrument similar credit status cash flow maturity period pledge group asset connection debt amount bank financial institution interest rate amount primarily denominate euro average approximately repayment date year million swiss franc million swiss franc year finance report roche group note roche group consolidate financial statement debt instrument recognise liability effective interest rate debt instrument million chf effective interest rate european medium term note programme bond october principal million euro bond august principal million pound sterling bond october principal million dollar swiss franc bond rodeo march principal billion swiss franc dollar bond chameleon july principal million dollar zero coupon dollar exchangeable note lyon july principal billion dollar japanese yen exchangeable bond sumo march principal billion japanese yen genentech senior note senior note july principal million dollar senior note july principal billion dollar senior note july principal million dollar japanese yen convertible bond issue chugai series chugai pharmaceutical unsecured convertible bond september principal billion japanese yen billion japanese yen total debt instrument unamortise discount include carry value debt instrument millions chf dollar bond sterle bond zero coupon dollar exchangeable note japanese yen exchangeable bond total unamortised discount fair value option disclose note group apply fair value option outstanding debt instrument group apply fair value hedge accounting past debt instrument european medium term note programme euro bond chameleon dollar bond rodeo swiss franc bond fair value option treatment base elimination accounting mismatch recognise hedging swap report fair value hedge bond report amortise cost difference carry value principal debt instrument total million swiss franc million swiss franc finance report roche group note roche group consolidate financial statement issue new debt instrument july genentech complete private placement billion dollar aggregate principal senior note placement consist million dollar senior note billion dollar senior note million dollar senior note senior note contain certain restrictive covenant incur property lien enter sale leaseback transaction cash inflow issue new debt instrument millions chf genentech senior note senior note issue july senior note issue july senior note issue july total cash inflow new issue year repayment redemption conversion debt instrument redemption sumo japanese yen exchangeable bond date march group redeem bond original issue plus accrue original issue discount oid effective interest rate bond cash outflow million swiss franc gain loss record redemption partial conversion repurchase lyon dollar exchangeable note january group repurchase option bondholder total dollar nominal value note total consideration million dollar million swiss franc equal carry value note total note carry value million swiss franc convert nonvoting equity security note repurchase call conversion represent number note outstanding start year material impact financial statement partial conversion series chugai pharmaceutical unsecured convertible bond bondswith face value billion japanese yen million swiss franc convert share chugai group percentage ownership chugai unaffected conversion group bond convertible chugai share mirror chugai outstanding party repayment redemption conversion debt instrument group converted redeem certain debt instrument debt reduce million swiss franc total cash outflow million swiss franc net pretax gain million swiss franc result show note net gain report exceptional item itsmateriality transaction describe conversion redemption lyon dollar exchangeable note march group exercise option note redemption april original issue plus accrue original issue discount oid effective interest rate note period april note principal million dollar call conversion holder remain note redeem cash april result conversion group ownership genentech decrease group realise pretax gain million swiss franc disposal interest genentech redemption remain note redemption lyon iii dollar exchangeable note april group exercise option note redemption original issue plus accrue original issue discount oid effective interest rate note note principal billion dollar redeem cash group realise pretax loss million swiss franc early redemption note finance report roche group note roche group consolidate financial statement partial redemption chameleon dollar bond june group announce tender offer redemption chameleon bond effective interest rate bond tender offer expire june pricing june point bond principal million dollar represent approximately outstanding bond tender redemption settlement june group realise pretax loss million swiss franc partial early redemption bond redemption limited conversion prefer stock mandatory redemption date november group redeem remain instrument original issue plus accrue interest effective interest rate instrument instrument principal million dollar redeem cash group realise gain loss redemption reassessment probable redemption date lyon dollar exchangeable note effective september group reassess likely future cash outflow instrument conclude wasappropriate consider date july probable date cash flow accordingly effective interest rate method group record pretax expense million swiss franc increase debt reflect increase carry value debt allow accrete value meet issue price plus accrue original issue discount oid july cash effect partial conversion series chugai pharmaceutical unsecured convertible bond bond face value billion japanese yen million swiss franc convert share chugai group percentage ownership chugai unaffected conversion group bond convertible chugai share mirror chugai outstanding party cash outflow repayment redemption debt instrument millions chf sumo japanese yen exchangeable bond lyon dollar exchangeable note lyon iii dollar exchangeable note chameleon dollar bond limit conversion prefer stock total cash outflow repayment redemption year term outstanding convertible debt instrument lyons note exchangeable nonvoting equity security nes american depositary share ad exchange ratio nes exchange adss usd principal maturity note group purchase note cash option holder july july july purchase price usd principal note usd usd usd respectively addition note redeemable option group time july issue price plus accrue original issue discount oid note outstanding december exchange require nonvoting equity security meet obligation series chugai pharmaceutical unsecured convertible bond bond jpy par value convertible share chugai conversion option bondholder time date september bond redeemable maturity issue price bond outstanding december convert require chugai share exactly meet obligation group percentage ownership chugai affect conversion group bond convertible chugai share mirror chugai outstanding party finance report roche group note roche group consolidate financial statement equity attributable roche shareholder change equity attributable roche shareholder millions chf share equity retain fair value hedge translation year end december capital instrument earnings reserve reserve reserve total january restate availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation income taxis item take directly transfer equity minority interest net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase convertible debt instrument change minority interest december include movement translation reserve million swiss franc relate consumer health otc business include calculation gain disposal business note finance report roche group note roche group consolidated financial statement share equity retain fair value hedge translation year end december capital instrument earnings reserve reserve reserve total january availableforsale investment valuation gain loss take equity transfer income statement sale impairment cash flow hedge gain loss take equity transfer income statement transfer initial balance sheet carrying value hedge item exchange difference translation foreign operation income taxis item take directly transfer equity minority interest net income recognise directly equity net income recognise income statement total recognise income expense dividend pay transaction equity instrument equity compensation plan genentech chugai share repurchase convertible debt instrument change minority interest december share capital december share capital roche holding ltd group parent company consist share nominal value swiss franc precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share describe note base information supply group novartis international ltd basel affiliates participation issue share nonvoting equity security genussscheine december nonvoting equity security issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate finance report roche group note roche group consolidate financial statement dividend february shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning board propose dividend business year swiss franc share nonvoting equity security subject approval annual general meeting february equity instruments holding equity instrument equivalent number nonvoting equity security december december nonvoting equity security low exercise price option derivative instrument total equity instrument equity instrument record equity original cost acquisition detail equity instrument hold december show table fair value disclose information purpose equity instrument december supplementary information equivalent number nonvoting strike price market value equity security maturity chf millions chf low exercise price option nov derivative instrument feb feb total nonvoting equity security low exercise price option mainly hold potential conversion obligation arise group convertible debt instrument note group potential obligation employee roche option plan roche stocksettle appreciation right note cover option exercisable time maturity group hold residual number option purchase use group previous option compensation scheme close net cash inflow transaction equity instrument million swiss franc net cash inflow million swiss franc group hold share reserve fair value reserve fair value reserve represent cumulative net change fair value available forsale financial asset asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc finance report roche group note roche group consolidate financial statement earning share nonvoting equity security basic earning share nonvoting equity security calculation basic earning share nonvoting equity security number share non vote equity security reduce weight average number nonvoting equity security hold group period basic earning share nonvoting equity security continue business group net income millions chf number share million number nonvoting equity security millions weight average number nonvoting equity security hold million weight average number share nonvoting equity security issue calculate basic earning share millions basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security net income weight average number share nonvoting equity security outstanding adjust effect dilutive potential share nonvoting equity security potential dilutive effect arise convertible debt instrument employee stock option plan outstanding convertible debt instrument convert lead reduction interest expense increase number share net dilutive effect earning share exercise outstanding vested employee stock option dilutive effect exercise outstanding vested genentech employee stock option dilutive effect net income genentech positive diluted earning share nonvoting equity security reflect potential impact dilutive effect earning share figure dilute earning share nonvoting equity security continue business group net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf increase minority share group net income net tax assume outstanding genentech stock option exercise millions chf net income calculate diluted earning share million chf weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf finance report roche group note roche group consolidate financial statement minority interest change equity attributable minority interest millions chf january restate net income recognise directly equity net income recognise income statement genentech chugai minority interest total net income recognise income statement total recognise income expense dividend pay minority shareholder equity compensation plans genentech chugai share repurchase convertible debt instrument change minority interest december genentech chugai minority interest total minority interest relate party control shareholder share capital roche holding ltd group parent company consist bearer share base information supply shareholder group pool voting right comprise vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri mscatherine oeri beatrice oeri maja oeri group hold share precede year represents issue share figure include share pooled voting right hold outside group individual member group andr hoffmann andreas oeri members board director roche holding ltd capacity receive annual remuneration swiss franc addition hoffmann oeri receive swiss franc swiss franc respectively time expense relate membership board committee transaction group individual member shareholder group subsidiary associate company list major group subsidiary associate company include note transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associated company finance report roche group note roche group consolidate financial statement key management personnel member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee remuneration board director chf compensation annual board committee remuneration member total executive director humer nonexecutive director gehrig hnggi bell brabeckletmathe ljr vink frey hoffmann julius oeri teltschik total nonexecutive director total remuneration board director remuneration gehrig include serve independent lead director vicechairman board remuneration hnggi include serve vicechairman board connection acquisition glycart july note group pay hnggi swiss franc consideration shareholding glycart equivalent amount pay shareholder glycart thepurchase shareholding remuneration nonexecutive member board director total million swiss franc remuneration member executive committee chf expense annual salary bonus allowance total humer burn hunziker keller jkc knowle von prondzynski total annual salary humer include swiss franc receive capacity member board director describe remuneration member executive committee total million swiss franc group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan member executive committee member executive committee participate roche connect employee stock purchase plan note finance report roche group note roche group consolidate financial statement indirect benefit employer contribution member executive committee chf social insurance pension roche connect humer burn hunziker keller jkc knowle von prondzynski total pension social insurance contribution pay group total million swiss franc roche longterm discuss note group implement new global longterm incentive programme available certain director management employee select discretion group programme consist stocksettle stock appreciation right ssar group alternative grant award exist roche option plan rop member executive committee grant ssar rop award roche performance share plan end member executive committee time award nonvoting equity security fair value million swiss franc respect group performance disclose note board approve new threeyear cycle roche performance share plan operate total award target member executive committee award result zero nonvoting equity security depend achievement performance target allocate recipient end blackout period end transaction member executive committee keller take mortgage loan swiss franc pension fund hoffmannla roche ltd interest rate theinterest rate loan fix december postemployment benefit plan transaction group postemployment define benefit plan employee thegroup describe note cash flow statement cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic business calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity include forexample taxis pay income bond conversion redemption cash generate operation million chf net income add nonoperate income expense income associate company financial income financing cost exceptional income bond conversion redemption income taxis discontinue business operate profit finance report roche group note roche group consolidate financial statement depreciation property plant equipment amortisation goodwill amortisation intangible asset impairment longterm asset change group organisation major legal case expense define benefit postemployment plan expense equitysettle equity compensation plan adjustments cash generate continue operation operate cash flow generate discontinued business cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect change group organisation cash generate group investment interest dividend receive millions chf interest receive dividend receive total cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity interest dividend pay millions chf interest pay dividend pay total significant noncash transaction significant noncash transaction significant noncash investing financing transaction include conversion lyon note genentech share note subsequent event significant event balance sheet date finance report roche group note roche group consolidated financial statement subsidiary associate company list company share capital equity interest country company city mill switzerland roche holding ltd basel chf stock exchange swx zurich valor share valor genussscheine isin share isin genussscheine market capitalisation chf mill basilea pharmaceutica ltd basel chf stock exchange swx bio zurich nasdaq biotech valor isin market capitalisation chf mill usa genentech inc south san francisco usd stock exchange new york incorporate delaware isin market capitalisation usd mill tripath imaging inc burlington usd stock exchange nasdaq isin market capitalisation usd mill japan chugai pharmaceutical ltd tokyo jpy stock exchange tokyo isin market capitalisation jpy mill great britain antisoma plc london gbp stock exchange london isin market capitalisation gbp mill nonliste company share capital equity interest country company city mill argentina producto roche qumica industrial buenos aire ars australia roche diagnostic australia pty limited castle hill aud roche product pty limited dee aud syntex australia limited north sydney aud austria roche austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh ltd dhaka bdt belgium roche brussels eur roche diagnostic belgium brussels eur bermuda canadian pharmholding ltd hamilton gbp corange international ltd hamilton usd corange ltd hamilton usd roche capital management ltd hamilton usd roche financial investments ltd hamilton usd roche financial services ltd hamilton usd roche interfinance ltd hamilton usd roche international ltd hamilton usd roche intertrade ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd brazil produto roche qumico farmacuticos paulo brl roche diagnostic brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd john usd chile producto farmoqumicos roche ltda santiago chile clp china roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai limited shanghai usd roche hong kong limited hong kong hkd roche center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche bogot cop finance report roche group note roche group consolidate financial statement share capital equity interest country company city mill costa rica roche servicios san jos usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostic hvidovre dkk dominican producto roche dominicana santo domingo dop republic ecuador roche ecuador quito usd salvador productos roche salvador san salvador usd estonia roche eesti tallinn eek finland roche espoo eur roche diagnostic espoo eur france cenexi sas fontenay sous bois eur roche diagnostic meylan eur roche sas neuillysurseine eur germany disetronic medical system gmbh sulzbach eur galenus mannheim gmbh mannheim eur hoffmannla roche aktiengesellschaft grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen dem roche diagnostic gmbh mannheim eur great britain roche diagnostic ltd lewes gbp roche hold limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp greece roche hellas athens eur guatemala producto roche guatemala guatemala gtq guernsey roche capital market international limited peter port chf roche financial market limited peter port chf honduras producto roche honduras tegucigalpa hnl hungary roche hungary ltd budapest huf india roche diagnostic india pvt ltd mumbai inr roche scientific company india private limited mumbai inr indonesia roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur italy roche diagnostic spa milan eur roche spa milan eur japan roche diagnostic tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius light luxembourg pharminvest luxembourg eur malaysia roche diagnostic malaysia sdn bhd kuala lumpur myr roche malaysia sdn bhd kuala lumpur myr mexico grupo roche syntex mxico mexico city mxn lakeside mxico mexico city mxn productos roche mexico city mxn syntex mexico city mxn morocco roche casablanca mad netherlands roche diagnostic nederland almere eur roche finance europe woerden eur roche nederland woerden eur roche pharmholde woerden eur new zealand roche diagnostic new zealand pty ltd auckland nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua managua nio norway roche norge oslo nok roche diagnostic norge oslo nok pakistan roche pakistan ltd karachi pkr finance report roche group note roche group consolidate financial statement share capital equity interest country company city mill panama producto roche interamericana panama city usd producto roche panam panama city pab roche capital corporation panama city usd syntex corporation panama city usd syntex puerto rico inc panama city usd technical development corp panama city usd peru producto roche qumica farmacutica lima pen philippine roche philippines inc makati php poland roche diagnostic polska warsaw pln roche polska warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas diagnsticos sociedade unipessoal lda lindaavelha eur romania roche romania srl bucharest ron russia roche moscow ltd moscow rub serbia roche doo beograd belgrade eur montenegro singapore roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd slovakia roche slovensko sro bratislava skk slovenia roche doo pharmaceutical company ljubljana sit south africa roche product proprietary limited johannesburg zar south korea roche diagnostics korea ltd seoul krw roche korea company ltd seoul krw spain andreu roche madrid eur roche diagnostic barcelona eur roche farma madrid eur syntex roche madrid eur sweden roche stockholm sek roche diagnostic scandinavia bromma sek switzerland disetronic handel burgdorf chf disetronic holding burgdorf chf disetronic licensing burgdorf chf disetronic medical systems burgdorf chf hoffmannla roche ltd basel chf glycart biotechnology ltd schlieren chf imib institute medical informatics biostatistics ltd basel chf rabbitair ltd zurichkloten chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd steinhausen chf roche finance ltd basel chf roche instrument center ltd rotkreuz chf roche capital market ltd basel chf roche pharma switzerland ltd reinach chf syntex corporation basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try uruguay roche international ltd montevideo uyu sapac corporation ltd montevideo uyu usa disetronic medical systems inc paul usd hoffmannla roche inc nutley usd igen international inc wilmington usd roche carolina inc florence usd roche colorado corporation boulder usd roche diagnostic corporation indianapoli usd roche finance america inc wilmington usd roche finance usa inc wilmington usd roche holdings inc wilmington usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche palo alto llc palo alto usd venezuela producto roche caracas veb share capital local currency unit finance report report group auditor report group auditor annual general meeting roche holding ltd basel group auditor audit consolidated financial statement income statement balance sheet cashflow statement statement recognise income expense statement change equity note page roche holding ltd year end december consolidated financial statement responsibility board director responsibility express opinion consolidated financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance swiss auditing standard international standard audit isa require audit plan perform obtain reasonable assurance consolidated financial statement free material misstatement examine test basis evidence support amount disclosure consolidated financial statement assess accounting principle significant estimate overall consolidated financial statement presentation believe audit provide reasonable basis opinion opinion consolidated financial statement true fair view financial position result operation cash flow accordance international financial reporting standard ifrs comply swiss law recommend consolidated financial statement submit approve kpmg klynveld peat marwick goerdeler john morris erik willems auditor charge basel january finance report multiyear overview statistic report statement income millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable minority interest addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend adjust chf cash warrant addition dividend unadjuste chf information table state report change accounting policy arise change international financial reporting standard stock split apply retrospectively net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum assume centenary warrant hold final exercise date dividend include special dividend relate spinoff fragrance flavour division dividend propose board director finance report roche group multiyear overview finance report roche group multiyear overview sale division millions chf pharmaceutical diagnostic consumer health otc vitamin fine chemical total sale geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic consumer health otc vitamin fine chemical corporate total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total finance report supplementary net income ep information group basic diluted earning share information give note consolidated financial statement supplementary eps information give net income exceptional item core net income additionally exclude amortisation intangible asset relate impact income taxis minority interest profit continue business exceptional item core net income million chf year end december profit continue business goodwill amortisation major legal case income taxis change group organisation income taxis exceptional financial income income taxis profit continue business exceptional item minority interest profit continue business goodwill amortisation net income attributable roche shareholder continue business exceptional item amortisation intangible asset income taxis minority interest core net income ep continue business exceptional item core eps ep continue business exceptional item core eps year end december net income attributable roche shareholder millions chf elimination interest expense net tax convertible debt instrument dilutive increase minority share net income net tax assume outstanding genentech chugai stock option exercise net income calculate diluted earning share share information million share nonvoting equity security weight average number share nonvoting equity security issue adjustment assume conversion convertible debt instrument dilutive adjustment assume exercise equity compensation plan dilutive weight average number share nonvoting equity security issue calculate diluted earning share earning share dilutedchf finance report roche security price development share chf roche share adjust swiss market index rebase price development nonvoting equ ity security genussschein chf roche nonvoting equity security adjust swiss market index rebase price development american depositary receipt adr usd roche adr adjust index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july information table restate stock split roche share nonvoting equity security genussscheine effective change ratio adrs effective january finance report roche group roche security number share nonvoting equity securitiesa number share nominal value chf number nonvoting equity security genussscheine nominal value total datum share nonvoting equity security chf net income equity dividend stock price shareb high low yearend stock price nonvoting equity security genussscheinb high low yearend market capitalisation millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price dividend propose board director ticker symbol share nonvoting equity security american depositary receipt reuters ros rogvx rhhbypk bloomberg rog rhhby swx swiss exchange rog finance report roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income gain disposal participation income group company income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year finance report roche holding ltd basel financial statement balance sheet december millions chf noncurrent asset participation longterm loan group company total noncurrent asset current asset shortterm loan group company account receivable group company account receivable marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision loan group company total noncurrent liability current liability account payable group company unrealise foreign currency gain liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value finance report note financial statement general financial statement roche holding ltd basel prepare accordance provision swiss law valuation method translation foreign currency marketable security report low cost market value asset include participation report cost appropriate writedown asset liability denominate foreign currency translate swiss franc yearend rate exchange participation translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer detail specific item taxis tax charge include corporate income capital taxis withhold taxis stamp duty equity movement recognise amount millions chf general share legal free special available total capital reserve reserve reserve earnings equity january net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december net income dividend pay transfer free reserve december share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc include equity non vote equity security genussscheine share capital confer voting right nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment share capital guarantee framework european medium term note emtn programme company issue guarantee favour group company amount million swiss franc previous year million swiss franc finance report roche holding ltd basel note financial statement time prepare balance sheet risk arise contingent liability discernible convertible option reference note consolidated financial statement equity instrument reference note consolidated financial statement pledge asset december asset pledge security company commitment previous year million swiss franc participation major participation list page important shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting february information available company previous year share shareholder group pool voting right comprise vera michalskihoffmann maja hoffmann andr hoffmann andreas oeri sabine duschmaloeri mscatherine oeri beatrice oeri maja oeria previous year share participation novartis international ltd basel include affiliate thereofb information supply shareholder figure share include share pooled voting right hold outside group individual member group figure december supply novartis international ltd basel finance report appropriation available earning proposal annual general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account finance report report statutory auditor report statutory auditor annual general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd year end december financial statement responsibility board director responsibility express opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance swiss auditing standard require audit plan perform obtain reasonable assurance financial statement free material misstatement examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate overall financial statement presentation believe audit provide reasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve kpmg klynveld peat marwick goerdeler john morris erik willems auditor charge basel january finance report publish cautionary statement forward fhoffmannla roche ltd look statement baselswitzerland annual report contain certain forwardlook tel ing statement forwardlooke statement fax identify word believe expect anticipate project intend media office seek estimate future similar expression corporate communication discussion thing strategy baselswitzerland goal plan intention factor tel cause actual result differ materially future fax reflect forwardlooke statement contain annual report investor relation pricing product initiative competitor baselswitzerland legislative regulatory development tel economic condition delay inability fax obtain regulatory approval bring prod uct market fluctuation currency world wide web exchange rate general financial market condi httpwwwrochecom tion uncertaintie discovery develop ment marketing new product new use order publication exist product include limitation tel negative result ofclinical trial research project fax unexpected sideeffect pipeline market emailbaselwebmasterrochecom product increase government pricing pre sure interruption production loss orinability obtain adequate protection intel lectual property right litigation loss key executive employeesand adverse publicity news coverage statement earning share growth profit forecast inter prete mean roche earning earning share subsequent period necessarily match exceed historical publish earning earning share ofroche annual general meeting february trademark mention enjoy legal protection roche annual report publish german original language english roche annual report issue hoffmannla roche ltd basel corporate communication finance report